US20220016075A1 - Methods for the treatment of mycobacterium infections - Google Patents
Methods for the treatment of mycobacterium infections Download PDFInfo
- Publication number
- US20220016075A1 US20220016075A1 US17/375,403 US202117375403A US2022016075A1 US 20220016075 A1 US20220016075 A1 US 20220016075A1 US 202117375403 A US202117375403 A US 202117375403A US 2022016075 A1 US2022016075 A1 US 2022016075A1
- Authority
- US
- United States
- Prior art keywords
- formula
- mycobacterium
- compound
- compounds
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 90
- 238000011282 treatment Methods 0.000 title abstract description 47
- 208000031998 Mycobacterium Infections Diseases 0.000 title description 6
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 48
- 208000015181 infectious disease Diseases 0.000 claims abstract description 26
- 241000186359 Mycobacterium Species 0.000 claims abstract description 15
- 206010024229 Leprosy Diseases 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 168
- 150000003839 salts Chemical class 0.000 claims description 71
- 239000000651 prodrug Substances 0.000 claims description 66
- 229940002612 prodrug Drugs 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 50
- 150000002148 esters Chemical class 0.000 claims description 46
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 10
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 8
- 229960003350 isoniazid Drugs 0.000 claims description 8
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 241001508003 Mycobacterium abscessus Species 0.000 claims description 7
- 229960001225 rifampicin Drugs 0.000 claims description 7
- 241000186367 Mycobacterium avium Species 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 241000186362 Mycobacterium leprae Species 0.000 claims description 5
- 241000178382 Mycobacterium lepromatosis Species 0.000 claims description 5
- 229960000285 ethambutol Drugs 0.000 claims description 5
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 5
- 229960002001 ethionamide Drugs 0.000 claims description 5
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims description 5
- 229960002599 rifapentine Drugs 0.000 claims description 5
- 241000186364 Mycobacterium intracellulare Species 0.000 claims description 4
- 229950009438 acedapsone Drugs 0.000 claims description 4
- 229960000860 dapsone Drugs 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 229960005206 pyrazinamide Drugs 0.000 claims description 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
- 241001467553 Mycobacterium africanum Species 0.000 claims description 3
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 claims description 3
- 241000178954 Mycobacterium avium subsp. silvaticum Species 0.000 claims description 3
- 241000186366 Mycobacterium bovis Species 0.000 claims description 3
- 241001312372 Mycobacterium canettii Species 0.000 claims description 3
- 241000211133 Mycobacterium caprae Species 0.000 claims description 3
- 241000187478 Mycobacterium chelonae Species 0.000 claims description 3
- 241000419175 Mycobacterium colombiense Species 0.000 claims description 3
- 241000186365 Mycobacterium fortuitum Species 0.000 claims description 3
- 241001494992 Mycobacterium indicus pranii Species 0.000 claims description 3
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 3
- 241000187492 Mycobacterium marinum Species 0.000 claims description 3
- 241000187919 Mycobacterium microti Species 0.000 claims description 3
- 241000699502 Mycobacterium mungi Species 0.000 claims description 3
- 241001457456 Mycobacterium pinnipedii Species 0.000 claims description 3
- 241000187489 Mycobacterium simiae Species 0.000 claims description 3
- 241001093674 Mycobacterium suricattae Species 0.000 claims description 3
- 241000187495 Mycobacterium terrae Species 0.000 claims description 3
- 241000187917 Mycobacterium ulcerans Species 0.000 claims description 3
- 241000187494 Mycobacterium xenopi Species 0.000 claims description 3
- 229960004287 clofazimine Drugs 0.000 claims description 3
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 3
- CKNYSJONUIBYCK-BZUAXINKSA-N desoxyfructo-serotonin Chemical compound C1=C(O)C=C2C(CCNCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO)=CNC2=C1 CKNYSJONUIBYCK-BZUAXINKSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 claims description 3
- 229960002229 sulfametoxydiazine Drugs 0.000 claims description 3
- 229960003433 thalidomide Drugs 0.000 claims description 3
- 241000656726 Mycobacterium orygis Species 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 72
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 70
- -1 isomers Substances 0.000 description 66
- 239000000203 mixture Substances 0.000 description 44
- 229940079593 drug Drugs 0.000 description 36
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 239000000546 pharmaceutical excipient Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 229920001223 polyethylene glycol Polymers 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000003755 preservative agent Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 240000003793 Rhizophora mangle Species 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- 235000019698 starch Nutrition 0.000 description 13
- 229920002125 Sokalan® Polymers 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- 230000002538 fungal effect Effects 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 229940032147 starch Drugs 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 238000002424 x-ray crystallography Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- ZQLIAKJHIRHCFA-XIIQHIPDSA-N [(7r)-5-chloro-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate Chemical compound O=C1[C@](C)(OC(C)=O)C(=O)C2=CN(CCO)C(/C=C/C(/C)=C/[C@@H](C)CC)=CC2=C1Cl ZQLIAKJHIRHCFA-XIIQHIPDSA-N 0.000 description 9
- 235000010443 alginic acid Nutrition 0.000 description 9
- 229920000615 alginic acid Polymers 0.000 description 9
- 229910052805 deuterium Inorganic materials 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 231100000252 nontoxic Toxicity 0.000 description 9
- 230000003000 nontoxic effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 230000000975 bioactive effect Effects 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000783 alginic acid Substances 0.000 description 7
- 229960001126 alginic acid Drugs 0.000 description 7
- 150000004781 alginic acids Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229960004756 ethanol Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- NFDKQFGUQFNACT-UTCJRWHESA-N pencolide Chemical compound C\C=C(C(O)=O)/N1C(=O)C=C(C)C1=O NFDKQFGUQFNACT-UTCJRWHESA-N 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- ZQLIAKJHIRHCFA-UHFFFAOYSA-N Isochromophilone VI Natural products O=C1C(C)(OC(C)=O)C(=O)C2=CN(CCO)C(C=CC(C)=CC(C)CC)=CC2=C1Cl ZQLIAKJHIRHCFA-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000003362 replicative effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- SAMXBYLRDCRTCV-HMSDUJDUSA-N 4-[7-acetyloxy-5-chloro-3-[(1e,3e)-3,5-dimethylhepta-1,3-dienyl]-7-methyl-6,8-dioxoisoquinolin-2-yl]butanoic acid Chemical compound O=C1C(C)(OC(C)=O)C(=O)C2=CN(CCCC(O)=O)C(/C=C/C(/C)=C/C(C)CC)=CC2=C1Cl SAMXBYLRDCRTCV-HMSDUJDUSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 241000120622 Rhizophoraceae Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229920001615 Tragacanth Polymers 0.000 description 5
- BTVUENFCNHCCNW-QPOFEPKDSA-N [(7R,8R,8aR)-3-[(E,3R,4R,5S)-3,4-dihydroxy-3,5-dimethylhept-1-enyl]-7-hydroxy-7-methyl-6-oxo-8,8a-dihydro-1H-isochromen-8-yl] acetate Chemical compound CC[C@H](C)[C@@H](O)[C@](C)(O)\C=C\C1=CC2=CC(=O)[C@](C)(O)[C@H](OC(C)=O)[C@H]2CO1 BTVUENFCNHCCNW-QPOFEPKDSA-N 0.000 description 5
- BPFKUKMOOOUEPT-QTKYNUCXSA-N [(7R,8R,8aR)-5-chloro-3-[(E,3S,4R,5S)-3,4-dihydroxy-3,5-dimethylhept-1-enyl]-7-hydroxy-7-methyl-6-oxo-8,8a-dihydro-1H-isochromen-8-yl] acetate Chemical compound CC[C@H](C)[C@@H](O)[C@@](C)(O)\C=C\C1=CC2=C(Cl)C(=O)[C@](C)(O)[C@H](OC(C)=O)[C@H]2CO1 BPFKUKMOOOUEPT-QTKYNUCXSA-N 0.000 description 5
- 235000010419 agar Nutrition 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000012216 bentonite Nutrition 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- SAMXBYLRDCRTCV-UHFFFAOYSA-N isochromophilone IX Natural products O=C1C(C)(OC(C)=O)C(=O)C2=CN(CCCC(O)=O)C(C=CC(C)=CC(C)CC)=CC2=C1Cl SAMXBYLRDCRTCV-UHFFFAOYSA-N 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- NFDKQFGUQFNACT-UHFFFAOYSA-N pencolide Natural products CC=C(C(O)=O)N1C(=O)C=C(C)C1=O NFDKQFGUQFNACT-UHFFFAOYSA-N 0.000 description 5
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000008247 solid mixture Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- ZMOXNUGOJSHBRR-SJNPAOOISA-N (7R,8R,8aR)-3-[(E,3R,4R,5S)-3,4-dihydroxy-3,5-dimethylhept-1-enyl]-7,8-dihydroxy-7-methyl-8,8a-dihydro-1H-isochromen-6-one Chemical compound CC[C@H](C)[C@@H](O)[C@](C)(O)\C=C\C1=CC2=CC(=O)[C@](C)(O)[C@H](O)[C@H]2CO1 ZMOXNUGOJSHBRR-SJNPAOOISA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- KYDNOVLBVBYOSW-UHFFFAOYSA-N Asterrinsaeuremethylester Natural products COC(=O)C1=CC(O)=CC(OC)=C1OC1=CC(C)=CC(O)=C1C(=O)OC KYDNOVLBVBYOSW-UHFFFAOYSA-N 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 4
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229940023476 agar Drugs 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- XOKVHFNTYHPEHN-UHFFFAOYSA-N asterric acid Chemical compound COC(=O)C1=CC(O)=CC(OC)=C1OC1=CC(C)=CC(O)=C1C(O)=O XOKVHFNTYHPEHN-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 229960003563 calcium carbonate Drugs 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000004049 epigenetic modification Effects 0.000 description 4
- 239000000054 fungal extract Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 239000004584 polyacrylic acid Substances 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229930000044 secondary metabolite Natural products 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 235000011078 sorbitan tristearate Nutrition 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- NUAKROUEBAHTAU-UHFFFAOYSA-N 4-hydroxy-6-methoxy-5-methyl-3h-2-benzofuran-1-one Chemical compound OC1=C(C)C(OC)=CC2=C1COC2=O NUAKROUEBAHTAU-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- ARZWKYJFXLHKCZ-YAOOYPAMSA-N C1=CC(OC)=CC=C1C(OC1=O)=CC2=C1C[C@]1(O)[C@@]3(C)CCC(=O)C(C)(C)[C@]3(O)CC[C@@]1(C)O2 Chemical compound C1=CC(OC)=CC=C1C(OC1=O)=CC2=C1C[C@]1(O)[C@@]3(C)CCC(=O)C(C)(C)[C@]3(O)CC[C@@]1(C)O2 ARZWKYJFXLHKCZ-YAOOYPAMSA-N 0.000 description 3
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 3
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 235000009255 Rhizophora mangle Nutrition 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000036981 active tuberculosis Diseases 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000002365 anti-tubercular Effects 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960003077 cycloserine Drugs 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229940055577 oleyl alcohol Drugs 0.000 description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001282 polysaccharide Chemical class 0.000 description 3
- 239000005017 polysaccharide Chemical class 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 2
- KZOIYIPDPQANFM-SNVBAGLBSA-N (4R)-14,16-dihydroxy-4-methyl-3-oxabicyclo[10.4.0]hexadeca-1(12),13,15-triene-2,6-dione Chemical compound C[C@@H]1CC(=O)CCCCCc2cc(O)cc(O)c2C(=O)O1 KZOIYIPDPQANFM-SNVBAGLBSA-N 0.000 description 2
- NXDFAIFYSGMTLP-PWSUYJOCSA-N (4R,8R)-8,14,16-trihydroxy-4-methyl-3-oxabicyclo[10.4.0]hexadeca-1(12),13,15-trien-2-one Chemical compound C[C@@H]1CCC[C@H](O)CCCc2cc(O)cc(O)c2C(=O)O1 NXDFAIFYSGMTLP-PWSUYJOCSA-N 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 238000001026 1H--1H correlation spectroscopy Methods 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 2
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 241000122229 Acinetobacter johnsonii Species 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VSUCUUMITHSNDI-JNQDVJLOSA-N C/C=C(/C(C)=O)N1C(=O)C=C(C)C1=O.CC[C@H](C)/C=C(C)/C=C/C1=CC2=C(Cl)C(=O)[C@](C)(OC(C)=O)C(=O)C2=CN1CCO.COC1=C(C)C(O)=C2CCC(=O)C2=C1.[H]C(=O)C1=C(O)C(C)=C(O)C=C1CC(=O)/C=C/C(C)=C/[C@@H](C)CC.[H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=C(Cl)C(=O)C(C)(O)C2OC(C)=O.[H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2O.[H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2OC(C)=O Chemical compound C/C=C(/C(C)=O)N1C(=O)C=C(C)C1=O.CC[C@H](C)/C=C(C)/C=C/C1=CC2=C(Cl)C(=O)[C@](C)(OC(C)=O)C(=O)C2=CN1CCO.COC1=C(C)C(O)=C2CCC(=O)C2=C1.[H]C(=O)C1=C(O)C(C)=C(O)C=C1CC(=O)/C=C/C(C)=C/[C@@H](C)CC.[H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=C(Cl)C(=O)C(C)(O)C2OC(C)=O.[H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2O.[H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2OC(C)=O VSUCUUMITHSNDI-JNQDVJLOSA-N 0.000 description 2
- XTUOJGUKVXTWON-BQYQJAHWSA-N CCC(C)C(O)C(C)(O)/C=C/C1=CC2=C(Cl)C(=O)C(C)(O)C(OC(C)=O)C2(O)CO1 Chemical compound CCC(C)C(O)C(C)(O)/C=C/C1=CC2=C(Cl)C(=O)C(C)(O)C(OC(C)=O)C2(O)CO1 XTUOJGUKVXTWON-BQYQJAHWSA-N 0.000 description 2
- MSSDDYWQZMIKRO-XSSIXYMVSA-N CCC(C)C(O)C(C)(O)/C=C/C1=CC2=C(Cl)C(=O)C(C)(O)C(OC(C)=O)C2(O)CO1.CC[C@H](C)/C=C(C)/C=C/C1=CC2=C(Cl)C(=O)[C@](O)(OC(C)=O)C(=O)C2=CN1CCCC(=O)O.[H]C(=O)C1=C(CC(=O)CO)C=C(OC)C(C)=C1O Chemical compound CCC(C)C(O)C(C)(O)/C=C/C1=CC2=C(Cl)C(=O)C(C)(O)C(OC(C)=O)C2(O)CO1.CC[C@H](C)/C=C(C)/C=C/C1=CC2=C(Cl)C(=O)[C@](O)(OC(C)=O)C(=O)C2=CN1CCCC(=O)O.[H]C(=O)C1=C(CC(=O)CO)C=C(OC)C(C)=C1O MSSDDYWQZMIKRO-XSSIXYMVSA-N 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- 241001409303 Laguncularia racemosa Species 0.000 description 2
- 206010065048 Latent tuberculosis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000235788 Mycobacterium frederiksbergense Species 0.000 description 2
- 241000187469 Mycobacterium neoaurum Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000228168 Penicillium sp. Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- FTTNXWIFPFEOQT-UHFFFAOYSA-N Territrem C Natural products COC1=C(O)C(OC)=CC(C=2OC(=O)C=3CC4(O)C5(C)C(=O)C=CC(C)(C)C5(O)CCC4(C)OC=3C=2)=C1 FTTNXWIFPFEOQT-UHFFFAOYSA-N 0.000 description 2
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 2
- 241001557886 Trichoderma sp. Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 2
- 0 [3*]C1=C(O)C(C(=O)[2*]O)=C(OC2=C(OC)C=C(O)C=C2C(=O)[1*]O)C=C1C Chemical compound [3*]C1=C(O)C(C(=O)[2*]O)=C(OC2=C(OC)C=C(O)C=C2C(=O)[1*]O)C=C1C 0.000 description 2
- DWAASDREHNIBNH-UHFFFAOYSA-N [H]C(=O)C1=C(CC(=O)CO)C=C(OC)C(C)=C1O Chemical compound [H]C(=O)C1=C(CC(=O)CO)C=C(OC)C(C)=C1O DWAASDREHNIBNH-UHFFFAOYSA-N 0.000 description 2
- ZMOXNUGOJSHBRR-VOTSOKGWSA-N [H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2O Chemical compound [H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2O ZMOXNUGOJSHBRR-VOTSOKGWSA-N 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- FNHNBWWIASUEQH-UHFFFAOYSA-N arisugacin B Natural products C1=CC(OC)=CC=C1C(OC1=O)=CC2=C1CC1(O)C3(C)C(=O)C=CC(C)(C)C3(O)CCC1(C)O2 FNHNBWWIASUEQH-UHFFFAOYSA-N 0.000 description 2
- FNHNBWWIASUEQH-HVWQDESWSA-N arisugacin B Chemical compound C1=CC(OC)=CC=C1C(OC1=O)=CC2=C1C[C@]1(O)[C@@]3(C)C(=O)C=CC(C)(C)[C@]3(O)CC[C@@]1(C)O2 FNHNBWWIASUEQH-HVWQDESWSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 description 2
- 229960000508 bedaquiline Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960004602 capreomycin Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 229940096529 carboxypolymethylene Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960000800 cetrimonium bromide Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019314 gum ghatti Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 230000005445 isotope effect Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 2
- 229960003907 linezolid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- XSBBWBWHNNKSSM-UHFFFAOYSA-N methyl 3-chloro-2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoate Chemical compound COC(=O)C1=CC(O)=CC(OC)=C1OC1=CC(C)=C(Cl)C(O)=C1C(=O)OC XSBBWBWHNNKSSM-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
- 229960003702 moxifloxacin Drugs 0.000 description 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229960002969 oleic acid Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 229940043349 potassium metabisulfite Drugs 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- 229940096992 potassium oleate Drugs 0.000 description 2
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960000918 protionamide Drugs 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229960000885 rifabutin Drugs 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 239000001589 sorbitan tristearate Substances 0.000 description 2
- 229960004129 sorbitan tristearate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- FTTNXWIFPFEOQT-JUDWXZBOSA-N territrem c Chemical compound COC1=C(O)C(OC)=CC(C=2OC(=O)C=3C[C@]4(O)[C@@]5(C)C(=O)C=CC(C)(C)[C@]5(O)CC[C@@]4(C)OC=3C=2)=C1 FTTNXWIFPFEOQT-JUDWXZBOSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960003231 thioacetazone Drugs 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940117013 triethanolamine oleate Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- GECAUTUYQKKNPV-PMYXRNIASA-N (1R,2R,5S,7S,10R)-5,7-dihydroxy-14-(4-methoxyphenyl)-2,6,6,10-tetramethyl-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-12(17),13-dien-16-one Chemical compound COc1ccc(cc1)-c1cc2O[C@]3(C)CC[C@@]4(O)C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3Cc2c(=O)o1 GECAUTUYQKKNPV-PMYXRNIASA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- SFCGEIHSBRXLDW-YWCGQCRUSA-N (3r,3ar,4ar,5s,9as)-3a-hydroxy-9a-methoxy-3,4a,5-trimethyl-2,3,4,5-tetrahydrobenzo[f][1]benzofuran-6-one Chemical compound C[C@@H]([C@@]1(C)C2)C(=O)C=CC1=C[C@@]1(OC)[C@]2(O)[C@H](C)CO1 SFCGEIHSBRXLDW-YWCGQCRUSA-N 0.000 description 1
- HPWIIERXAFODPP-GHBBWTPBSA-N (3r,4r)-3,6-diamino-n-[(3s,6z,9s,12s,15s)-3-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]-4-hydroxyhexanamide Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)[C@H](O)CCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)NCC1 HPWIIERXAFODPP-GHBBWTPBSA-N 0.000 description 1
- AOWCMVPFOMNSMB-SNVBAGLBSA-N (4R)-14,16-dihydroxy-4-methyl-3-oxabicyclo[10.4.0]hexadeca-1(12),13,15-triene-2,8-dione Chemical compound C[C@@H]1CCCC(=O)CCCc2cc(O)cc(O)c2C(=O)O1 AOWCMVPFOMNSMB-SNVBAGLBSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- AVVJEAPNVWBPQC-UHFFFAOYSA-N 5-hydroxy-2-(3-hydroxy-2-methoxycarbonyl-5-methylphenoxy)-3-methoxybenzoic acid Chemical compound COC(=O)C1=C(O)C=C(C)C=C1OC1=C(OC)C=C(O)C=C1C(O)=O AVVJEAPNVWBPQC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000069378 Aegiceras corniculatum Species 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000131830 Avicennia germinans Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- DEMKVZWZHPSECV-HQHGKODGSA-N CC[C@H](C)/C=C(C)/C=C/C(=O)CC1=C(C=O)C(O)C(C)C(O)C1 Chemical compound CC[C@H](C)/C=C(C)/C=C/C(=O)CC1=C(C=O)C(O)C(C)C(O)C1 DEMKVZWZHPSECV-HQHGKODGSA-N 0.000 description 1
- HKMRSUOHGNZICR-IKKZITNWSA-N CC[C@H](C)/C=C(C)/C=C/C1=CC2=C(Cl)C(=O)[C@](O)(OC(C)=O)C(=O)C2=CN1CCCC(=O)O Chemical compound CC[C@H](C)/C=C(C)/C=C/C1=CC2=C(Cl)C(=O)[C@](O)(OC(C)=O)C(=O)C2=CN1CCCC(=O)O HKMRSUOHGNZICR-IKKZITNWSA-N 0.000 description 1
- UJIZXRHKHHFYLL-KHZWJUMCSA-N COC1=CC(C2=CC3=C(C[C@]4(O)[C@@]5(C)C(=O)C=CC(C)(C)[C@]5(O)CC[C@@]4(C)O3)C(=O)O2)=CC(OC)=C1O.COC1=CC=C(C2=CC3=C(C[C@]4(O)[C@@]5(C)C(=O)C=CC(C)(C)[C@]5(O)CC[C@@]4(C)O3)C(=O)O2)C=C1.[H][C@@]1(COC=O)CC[C@]2(C)[C@@]3(O)CC4=C(C=C(C5=CC=C(OC)C=C5)OC4=O)O[C@]3(C)CC[C@@]2(O)C1(C)C.[H][C@]1(O)CC[C@@]2(C)[C@@](O)(CC[C@@]3(C)OC4=C(C[C@@]32[H])C(=O)OC(C2=CC=C(OC)C=C2)=C4)C1(C)C Chemical compound COC1=CC(C2=CC3=C(C[C@]4(O)[C@@]5(C)C(=O)C=CC(C)(C)[C@]5(O)CC[C@@]4(C)O3)C(=O)O2)=CC(OC)=C1O.COC1=CC=C(C2=CC3=C(C[C@]4(O)[C@@]5(C)C(=O)C=CC(C)(C)[C@]5(O)CC[C@@]4(C)O3)C(=O)O2)C=C1.[H][C@@]1(COC=O)CC[C@]2(C)[C@@]3(O)CC4=C(C=C(C5=CC=C(OC)C=C5)OC4=O)O[C@]3(C)CC[C@@]2(O)C1(C)C.[H][C@]1(O)CC[C@@]2(C)[C@@](O)(CC[C@@]3(C)OC4=C(C[C@@]32[H])C(=O)OC(C2=CC=C(OC)C=C2)=C4)C1(C)C UJIZXRHKHHFYLL-KHZWJUMCSA-N 0.000 description 1
- JRJCAMNJERVVGV-CPHQRDPUSA-N C[C@@H]1C(=O)C=CC2=C[C@]3(O)OC[C@H](C)[C@]3(O)C[C@@]21C.C[C@@H]1CC(=O)CCCCCC2=CC(O)=CC(O)=C2C(=O)O1.C[C@@H]1CCCC(=O)CCCC2=CC(O)=CC(O)=C2C(=O)O1.C[C@@H]1CCC[C@H](O)CCCC2=CC(O)=CC(O)=C2C(=O)O1.C[C@H]1CO[C@@]2(O)C=C3C=CC(=O)[C@H](C)[C@@]3(C)C[C@@]12O Chemical compound C[C@@H]1C(=O)C=CC2=C[C@]3(O)OC[C@H](C)[C@]3(O)C[C@@]21C.C[C@@H]1CC(=O)CCCCCC2=CC(O)=CC(O)=C2C(=O)O1.C[C@@H]1CCCC(=O)CCCC2=CC(O)=CC(O)=C2C(=O)O1.C[C@@H]1CCC[C@H](O)CCCC2=CC(O)=CC(O)=C2C(=O)O1.C[C@H]1CO[C@@]2(O)C=C3C=CC(=O)[C@H](C)[C@@]3(C)C[C@@]12O JRJCAMNJERVVGV-CPHQRDPUSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940122799 Dihydropteroate synthase inhibitor Drugs 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 108010038532 Enviomycin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 241000384508 Hoplostethus atlanticus Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- ZYZWUJQEZGXAGI-UHFFFAOYSA-N Isochromophilone IV Natural products CCC(C)C=C(/C)C=CC1=CC2=C(Cl)C(=O)C(C)(O)C(O)C2(CO1)C(=O)C ZYZWUJQEZGXAGI-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000533950 Leucojum Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001332087 Mycobacterium abscessus subsp. bolletii Species 0.000 description 1
- 241001105445 Mycobacterium abscessus subsp. massiliense Species 0.000 description 1
- 241001509442 Mycobacterium agri Species 0.000 description 1
- 241000957223 Mycobacterium alvei Species 0.000 description 1
- 241001371945 Mycobacterium aquaticum Species 0.000 description 1
- 241000594851 Mycobacterium arabiense Species 0.000 description 1
- 241001318887 Mycobacterium aromaticivorans Species 0.000 description 1
- 241001368179 Mycobacterium arosiense Species 0.000 description 1
- 241000687894 Mycobacterium arupense Species 0.000 description 1
- 241001332085 Mycobacterium aubagnense Species 0.000 description 1
- 241000187473 Mycobacterium aurum Species 0.000 description 1
- 241001532520 Mycobacterium austroafricanum Species 0.000 description 1
- 241000871709 Mycobacterium bacteremicum Species 0.000 description 1
- 241001332069 Mycobacterium barrassiae Species 0.000 description 1
- 241001316387 Mycobacterium boenickei Species 0.000 description 1
- 241000567118 Mycobacterium bohemicum Species 0.000 description 1
- 241001662551 Mycobacterium botniense Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000157299 Mycobacterium branderi Species 0.000 description 1
- 241001316365 Mycobacterium brisbanense Species 0.000 description 1
- 241001674312 Mycobacterium brumae Species 0.000 description 1
- 241000318680 Mycobacterium canariasense Species 0.000 description 1
- 241001134667 Mycobacterium celatum Species 0.000 description 1
- 241000254210 Mycobacterium chimaera Species 0.000 description 1
- 241000187472 Mycobacterium chitae Species 0.000 description 1
- 241001524108 Mycobacterium chlorophenolicum Species 0.000 description 1
- 241000187913 Mycobacterium chubuense Species 0.000 description 1
- 241000761550 Mycobacterium conceptionense Species 0.000 description 1
- 241000178318 Mycobacterium conspicuum Species 0.000 description 1
- 241000187487 Mycobacterium cookii Species 0.000 description 1
- 241001420379 Mycobacterium cosmeticum Species 0.000 description 1
- 241000187912 Mycobacterium diernhoferi Species 0.000 description 1
- 241000587727 Mycobacterium doricum Species 0.000 description 1
- 241001532524 Mycobacterium duvalii Species 0.000 description 1
- 241001609973 Mycobacterium elephantis Species 0.000 description 1
- 241000187471 Mycobacterium fallax Species 0.000 description 1
- 241000187911 Mycobacterium farcinogenes Species 0.000 description 1
- 241001136226 Mycobacterium florentinum Species 0.000 description 1
- 241001295721 Mycobacterium fortuitum subsp. acetamidolyticum Species 0.000 description 1
- 241000187470 Mycobacterium gadium Species 0.000 description 1
- 241000187485 Mycobacterium gastri Species 0.000 description 1
- 241001509451 Mycobacterium genavense Species 0.000 description 1
- 241000187910 Mycobacterium gilvum Species 0.000 description 1
- 241000936963 Mycobacterium goodii Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241001147828 Mycobacterium haemophilum Species 0.000 description 1
- 241000202700 Mycobacterium hassiacum Species 0.000 description 1
- 241000142650 Mycobacterium heckeshornense Species 0.000 description 1
- 241000520088 Mycobacterium heidelbergense Species 0.000 description 1
- 241001147834 Mycobacterium hiberniae Species 0.000 description 1
- 241000245945 Mycobacterium hodleri Species 0.000 description 1
- 241001644172 Mycobacterium holsaticum Species 0.000 description 1
- 241001316369 Mycobacterium houstonense Species 0.000 description 1
- 241001086787 Mycobacterium icosiumassiliensis Species 0.000 description 1
- 241001646019 Mycobacterium immunogenum Species 0.000 description 1
- 241001467535 Mycobacterium interjectum Species 0.000 description 1
- 241001136174 Mycobacterium intermedium Species 0.000 description 1
- 241001166087 Mycobacterium iranicum Species 0.000 description 1
- 241000187483 Mycobacterium komossense Species 0.000 description 1
- 241000516643 Mycobacterium kubicae Species 0.000 description 1
- 241000439014 Mycobacterium lacus Species 0.000 description 1
- 241001248583 Mycobacterium lentiflavum Species 0.000 description 1
- 241000035554 Mycobacterium liflandii Species 0.000 description 1
- 241000755466 Mycobacterium llatzerense Species 0.000 description 1
- 241001553029 Mycobacterium madagascariense Species 0.000 description 1
- 241000520670 Mycobacterium mageritense Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241001673077 Mycobacterium monacense Species 0.000 description 1
- 241001672738 Mycobacterium montefiorense Species 0.000 description 1
- 241001532511 Mycobacterium moriokaense Species 0.000 description 1
- 241001062465 Mycobacterium murale Species 0.000 description 1
- 241001013798 Mycobacterium nebraskense Species 0.000 description 1
- 241001316374 Mycobacterium neworleansense Species 0.000 description 1
- 241000187491 Mycobacterium nonchromogenicum Species 0.000 description 1
- 241000611872 Mycobacterium novocastrense Species 0.000 description 1
- 241000187918 Mycobacterium obuense Species 0.000 description 1
- 241001659709 Mycobacterium palustre Species 0.000 description 1
- 241001532512 Mycobacterium parafortuitum Species 0.000 description 1
- 241000961132 Mycobacterium parascrofulaceum Species 0.000 description 1
- 241001101480 Mycobacterium parmense Species 0.000 description 1
- 241000168058 Mycobacterium peregrinum Species 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 241001332086 Mycobacterium phocaicum Species 0.000 description 1
- 241001532509 Mycobacterium porcinum Species 0.000 description 1
- 241001532510 Mycobacterium poriferae Species 0.000 description 1
- 241000089536 Mycobacterium pseudoshottsii Species 0.000 description 1
- 241001606460 Mycobacterium psychrotolerans Species 0.000 description 1
- 241001509447 Mycobacterium pulveris Species 0.000 description 1
- 241001115881 Mycobacterium pyrenivorans Species 0.000 description 1
- 241000224454 Mycobacterium saskatchewanense Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241000594848 Mycobacterium sediminis Species 0.000 description 1
- 241000187468 Mycobacterium senegalense Species 0.000 description 1
- 241000542760 Mycobacterium seoulense Species 0.000 description 1
- 241000409180 Mycobacterium septicum Species 0.000 description 1
- 241001147832 Mycobacterium shimoidei Species 0.000 description 1
- 241000919916 Mycobacterium shottsii Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187497 Mycobacterium sphagni Species 0.000 description 1
- 241000763716 Mycobacterium stephanolepidis Species 0.000 description 1
- 241000187496 Mycobacterium szulgai Species 0.000 description 1
- 241001067171 Mycobacterium talmoniae Species 0.000 description 1
- 241000187477 Mycobacterium thermoresistibile Species 0.000 description 1
- 241001532502 Mycobacterium tokaiense Species 0.000 description 1
- 241000218972 Mycobacterium triplex Species 0.000 description 1
- 241001293520 Mycobacterium tusciae Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- 241000142559 Mycobacterium vanbaalenii Species 0.000 description 1
- 241000611277 Mycobacterium wolinskyi Species 0.000 description 1
- 241000969523 Mycobacterium yongonense Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000224438 Naegleria fowleri Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000985522 Penicillium sclerotiorum Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241001335017 Pleosporales sp. Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
- 244000284012 Vetiveria zizanioides Species 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- MMOJJYPBNVVCGY-CTQGMABPSA-N [(7r,8r,8ar)-5-chloro-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dienyl]-7-hydroxy-7-methyl-6-oxo-8,8a-dihydro-1h-isochromen-8-yl] acetate Chemical compound O=C1[C@](C)(O)[C@H](OC(C)=O)[C@H]2COC(/C=C/C(/C)=C/[C@@H](C)CC)=CC2=C1Cl MMOJJYPBNVVCGY-CTQGMABPSA-N 0.000 description 1
- HNVJWWBKFFDQAA-NRKPLWJESA-N [(7r,8r,8ar)-7-hydroxy-7-methyl-6-oxo-3-[(e)-prop-1-enyl]-8,8a-dihydro-1h-isochromen-8-yl] 2,4-dihydroxy-6-methylbenzoate Chemical class O([C@H]1[C@@](C)(O)C(=O)C=C2C=C(OC[C@@H]21)/C=C/C)C(=O)C1=C(C)C=C(O)C=C1O HNVJWWBKFFDQAA-NRKPLWJESA-N 0.000 description 1
- SRUILBLGVMJFPG-YDROHTJRSA-N [H]C(=O)C1=C(O)C(C)=C(O)C=C1CC(=O)/C=C/C(C)=C/[C@@H](C)CC Chemical compound [H]C(=O)C1=C(O)C(C)=C(O)C=C1CC(=O)/C=C/C(C)=C/[C@@H](C)CC SRUILBLGVMJFPG-YDROHTJRSA-N 0.000 description 1
- BPFKUKMOOOUEPT-BQYQJAHWSA-N [H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=C(Cl)C(=O)C(C)(O)C2OC(C)=O Chemical compound [H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=C(Cl)C(=O)C(C)(O)C2OC(C)=O BPFKUKMOOOUEPT-BQYQJAHWSA-N 0.000 description 1
- BTVUENFCNHCCNW-BQYQJAHWSA-N [H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2OC(C)=O Chemical compound [H]C12COC(/C=C/C(C)(O)C(O)C(C)CC)=CC1=CC(=O)C(C)(O)C2OC(C)=O BTVUENFCNHCCNW-BQYQJAHWSA-N 0.000 description 1
- ZFJSQMZNZSWOPM-PGJNLMOESA-N [H][C@@]1(CC/C(C)=C\C(=O)O)C(C)=CC(=O)CC1(C)C Chemical compound [H][C@@]1(CC/C(C)=C\C(=O)O)C(C)=CC(=O)CC1(C)C ZFJSQMZNZSWOPM-PGJNLMOESA-N 0.000 description 1
- BPFKUKMOOOUEPT-ZFXSVMKZSA-N [H][C@]12COC(/C=C/[C@@](C)(O)[C@H](O)[C@@H](C)CC)=CC1=C(Cl)C(=O)[C@](C)(O)[C@@H]2OC(C)=O Chemical compound [H][C@]12COC(/C=C/[C@@](C)(O)[C@H](O)[C@@H](C)CC)=CC1=C(Cl)C(=O)[C@](C)(O)[C@@H]2OC(C)=O BPFKUKMOOOUEPT-ZFXSVMKZSA-N 0.000 description 1
- ROXSTEMBUXKWPE-PDYDAKFHSA-N [H][C@]12COC(/C=C/[C@@](C)(O)[C@H](O)[C@@H](C)CC)=CC1=C(Cl)C(=O)[C@](C)(O)[C@@H]2OC(C)=O.[H][C@]12COC(/C=C/[C@](C)(O)[C@H](O)[C@@H](C)CC)=CC1=C(Cl)C(=O)[C@](C)(O)[C@@H]2OC(C)=O Chemical compound [H][C@]12COC(/C=C/[C@@](C)(O)[C@H](O)[C@@H](C)CC)=CC1=C(Cl)C(=O)[C@](C)(O)[C@@H]2OC(C)=O.[H][C@]12COC(/C=C/[C@](C)(O)[C@H](O)[C@@H](C)CC)=CC1=C(Cl)C(=O)[C@](C)(O)[C@@H]2OC(C)=O ROXSTEMBUXKWPE-PDYDAKFHSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 229920006322 acrylamide copolymer Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- NEDPPCHNEOMTJV-UHFFFAOYSA-N aldesulfone Chemical compound C1=CC(NCS(=O)O)=CC=C1S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1 NEDPPCHNEOMTJV-UHFFFAOYSA-N 0.000 description 1
- 229960004971 aldesulfone sodium Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 108010039311 arabinosyltransferase Proteins 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- LHKWCVMCNOROFZ-MCPFUKIPSA-N arisugacin D Chemical compound C1=CC(OC)=CC=C1C(OC1=O)=CC2=C1C[C@]1(O)[C@@]3(C)CC[C@@H](OC(C)=O)C(C)(C)[C@]3(O)CC[C@@]1(C)O2 LHKWCVMCNOROFZ-MCPFUKIPSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 235000001053 badasse Nutrition 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229940046925 calcium aminosalicylate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 229960002283 calcium glubionate Drugs 0.000 description 1
- 229940078512 calcium gluceptate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
- OKRXSXDSNLJCRS-NLOQLBMISA-L calcium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate;hydrate Chemical compound O.[Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O OKRXSXDSNLJCRS-NLOQLBMISA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- XDWVNCOPMIEDJK-UHFFFAOYSA-L calcium;5-amino-2-carboxyphenolate Chemical compound [Ca+2].NC1=CC=C(C([O-])=O)C(O)=C1.NC1=CC=C(C([O-])=O)C(O)=C1 XDWVNCOPMIEDJK-UHFFFAOYSA-L 0.000 description 1
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- DVAIYSZTXVOUQZ-UHFFFAOYSA-N diucifon Chemical compound N1C(=O)NC(=O)C(S(=O)(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C=CC(NS(=O)(=O)C=3C(NC(=O)NC=3C)=O)=CC=2)=C1C DVAIYSZTXVOUQZ-UHFFFAOYSA-N 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229950000219 enviomycin Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000004340 gradient COSY Methods 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 244000056931 lavandin Species 0.000 description 1
- 235000009606 lavandin Nutrition 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GQZQCROBCYNTMU-UHFFFAOYSA-N methaniazide Chemical compound OS(=O)(=O)CNNC(=O)C1=CC=NC=C1 GQZQCROBCYNTMU-UHFFFAOYSA-N 0.000 description 1
- 229950007577 methaniazide Drugs 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229930183164 microsphaeropsisin Natural products 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003592 new natural product Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000005954 phosphonylation reaction Methods 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- SGHWBDUXKUSFOP-KYALZUAASA-N rifalazil Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N=C2C(=O)C=3C(O)=C4C)C)OC)C4=C1C=3C(NC1=C(O)C=3)=C2OC1=CC=3N1CCN(CC(C)C)CC1 SGHWBDUXKUSFOP-KYALZUAASA-N 0.000 description 1
- 229950005007 rifalazil Drugs 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940046927 sodium aminosalicylate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical compound [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- GMUQJDAYXZXBOT-UHFFFAOYSA-M sodium;4-amino-2-hydroxybenzoate;dihydrate Chemical compound O.O.[Na+].NC1=CC=C(C([O-])=O)C(O)=C1 GMUQJDAYXZXBOT-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- FNDDDNOJWPQCBZ-ZDUSSCGKSA-N sutezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCSCC1 FNDDDNOJWPQCBZ-ZDUSSCGKSA-N 0.000 description 1
- 229950000448 sutezolid Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- ODKYYBOHSVLGNU-IAGONARPSA-N terizidone Chemical compound O=C1NOCC1\N=C\C(C=C1)=CC=C1\C=N\C1C(=O)NOC1 ODKYYBOHSVLGNU-IAGONARPSA-N 0.000 description 1
- 229960003457 terizidone Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- BWBONKHPVHMQHE-UHFFFAOYSA-N tiocarlide Chemical compound C1=CC(OCCC(C)C)=CC=C1NC(=S)NC1=CC=C(OCCC(C)C)C=C1 BWBONKHPVHMQHE-UHFFFAOYSA-N 0.000 description 1
- 229960002171 tiocarlide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000010679 vetiver oil Substances 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Definitions
- the present disclosure is directed to methods for treating Mycobacterium infections such as tuberculosis or leprosy.
- Tuberculosis is a common and often deadly infectious caused by Mycobacterium tuberculosis bacteria. Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections are latent (i.e. do not have symptoms), but about 10% of latent tuberculosis infections progress to active disease which can kill about half of those affected if left untreated. The class symptoms of tuberculosis are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. Infection of other organ can lead to a wider range of symptoms.
- tuberculosis Treatment for tuberculosis is difficult, requiring long-term administration of antibiotics.
- a patient For treatment of active tuberculosis, a patient is typically administered isoniazid (with pyridoxal phosphate), rifampin, pyrazinamide, and ethambutol daily for two months, followed by administration of isoniazid and rifampin daily for a further four months.
- the standard treatment is administration of isoniazid alone for three months or three months of weekly isoniazide/rifapentine combination therapy.
- Antibiotic resistance is a growing problem for tuberculosis, with treatment regimens for resistant strains requiring the administration of stronger drugs over longer time periods. Some strains of tuberculosis are completely resistant to all currently used drugs.
- the disclosed subject matter in one aspect, relates to methods for the treatment of infections and other disorders caused by Mycobacterium , for example tuberculosis or leprosy.
- a method of treating an infection with a Mycobacterium in a subject comprising administering a therapeutically effective amount of one or more compounds selected from:
- the one or more compounds, or pharmaceutically acceptable salts, prodrugs, or esters thereof are administered in combination with a pharmaceutically acceptable carrier to form a pharmaceutical composition.
- the infection comprises tuberculosis.
- the infection is caused by Mycobacterium africanum, Mycobacterium bovis, Mycobacterium canetti, Mycobacterium caprae, Mycobacterium microti, Mycobacterium mungi, Mycobacterium orygis, Mycobacterium pinnipedii, Mycobacterium suricattae , or Mycobacterium tuberculosis.
- the infection comprises leprosy. In some embodiments, the infection is caused by Mycobacterium leprae or Mycobacterium lepromatosis.
- the infection is caused by Mycobacterium avium, Mycobacterium avium paratuberculosis, Mycobacterium avium silvaticum, Mycobacterium avium hominissuis, Mycobacterium colombiense, Mycobacterium indicus pranii, Mycobacterium intracellulare, Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum, mycobacterium terrae, Mycobacterium xenopi , and Mycobacterium simiae.
- the one or more compounds are administered in combination or alternation with one or more additional therapeutic agents, for example ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, acedapsone, clofazimine, dapsone, desoxyfructo-serotonin, ethionamide, rifapentine, sulfameter, thalidomide, or combinations thereof.
- additional therapeutic agents for example ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, acedapsone, clofazimine, dapsone, desoxyfructo-serotonin, ethionamide, rifapentine, sulfameter, thalidomide, or combinations thereof.
- the subject is a human.
- a method for killing one or more Mycobacterium cells comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- a method for inhibiting the growth of one or more Mycobacterium cells comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- FIG. 1 shows an isolation plate for fungal strain EG12-25A-3 as further described in the examples.
- FIG. 2 shows THE separation scheme for EG12-25A-3-DNMT as further described in the examples.
- FIG. 3 shows the isolation scheme for BFY3 as further described in the examples.
- FIG. 4 shows the key COSY (bolded lines) and HMBC (black arrows) of BFY-3.
- FIG. 5 shows the isolating scheme for BFY4 as further described in the examples.
- FIG. 6 shows the x-ray crystallography structure of BFY-4.
- FIG. 7 shows the x-ray crystallography structure of Fraction D.
- FIG. 8 shows the x-ray crystallography structure of Fraction O-7.
- FIG. 9 shows the x-ray crystallography structure of Fraction F-8-3.
- FIG. 10 shows the x-ray crystallography structure of Fraction G-4.
- FIG. 11 shows the bioactivity and cytotoxicity of Fraction O-7 obtained as further described in the examples.
- an agent includes a plurality of agents, including mixtures thereof.
- the terms “may,” “optionally,” and “may optionally” are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur.
- the statement that a formulation “may include an excipient” is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.
- Administration to a subject includes any route of introducing or delivering to a subject an agent. Administration can be carried out by any suitable route, including oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques), and the like.
- parenteral e.g., subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques
- Constant administration means that the compounds are administered at the same point in time or essentially immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.
- Systemic administration refers to the introducing or delivering to a subject an agent via a route which introduces or delivers the agent to extensive areas of the subject's body (e.g. greater than 50% of the body), for example through entrance into the circulatory or lymph systems.
- local administration refers to the introducing or delivery to a subject an agent via a route which introduces or delivers the agent to the area or area immediately adjacent to the point of administration and does not introduce the agent systemically in a therapeutically significant amount.
- locally administered agents are easily detectable in the local vicinity of the point of administration but are undetectable or detectable at negligible amounts in distal parts of the subject's body.
- Administration includes self-administration and the administration by another.
- beneficial agent and “active agent” are used interchangeably herein to refer to a chemical compound or composition that has a beneficial biological effect.
- beneficial biological effects include both therapeutic effects, i.e., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, i.e., prevention of a disorder or other undesirable physiological condition.
- the terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, and the like.
- treating or “treatment” of a subject includes the administration of a drug to a subject with the purpose of preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder.
- the terms “treating” and “treatment” can also refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage.
- the term “preventing” a disorder or unwanted physiological event in a subject refers specifically to the prevention of the occurrence of symptoms and/or their underlying cause, wherein the subject may or may not exhibit heightened susceptibility to the disorder or event.
- an “effective amount” of a therapeutic agent is meant a nontoxic but sufficient amount of a beneficial agent to provide the desired effect.
- the amount of beneficial agent that is “effective” will vary from subject to subject, depending on the age and general condition of the subject, the particular beneficial agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount”. However, an appropriate “effective” amount in any subject case may be determined by one of ordinary skill in the art using routine experimentation. Also, as used herein, and unless specifically stated otherwise, an “effective amount” of a beneficial can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.
- an “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- a “therapeutically effective amount” of a therapeutic agent refers to an amount that is effective to achieve a desired therapeutic result
- a “prophylactically effective amount” of a therapeutic agent refers to an amount that is effective to prevent an unwanted physiological condition.
- Therapeutically effective and prophylactically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the subject.
- the term “therapeutically effective amount” can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect.
- the precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
- the term “pharmaceutically acceptable” component can refer to a component that is not biologically or otherwise undesirable, i.e., the component may be incorporated into a pharmaceutical formulation of the invention and administered to a subject as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained.
- pharmaceutically acceptable refers to an excipient, it is generally implied that the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
- “Pharmaceutically acceptable carrier” (sometimes referred to as a “carrier”) means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and includes a carrier that is acceptable for veterinary and/or human pharmaceutical or therapeutic use.
- carrier or “pharmaceutically acceptable carrier” can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil/water or water/oil emulsion) and/or various types of wetting agents.
- carrier encompasses, but is not limited to, any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations and as described further herein.
- “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, non-toxic, acid or base addition salts thereof.
- the salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- salts of the present compounds further include solvates of the compounds and of the compound salts.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disuifonic, oxalic, isethionic, HOOC—(CH2)n-COOH where n is 0-4, and the like, or using a different acid that produces the same counterion.
- Lists of additional suitable salts may be found, e.g.,
- the term “pharmacologically active” can refer to a derivative or analog (e.g., a salt, ester, amide, conjugate, metabolite, isomer, fragment, etc.) having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
- the term “subject” or “host” can refer to living organisms such as mammals, including, but not limited to humans, livestock, dogs, cats, and other mammals. Administration of the therapeutic agents can be carried out at dosages and for periods of time effective for treatment of a subject. In some embodiments, the subject is a human.
- the compounds described herein include enantiomers, mixtures of enantiomers, diastereomers, tautomers, racemates and other isomers, such as rotamers, as if each is specifically described, unless otherwise indicated or otherwise excluded by context. It is to be understood that the compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R-) or (S-) configuration. The compounds provided herein may either be enantiomerically pure, or be diastereomeric or enantiomeric mixtures. It is to be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo.
- the compounds described herein can be used to treat or prevent a disease, disorder, or condition in a patient in need thereof that is the result of an infection by a Mycobacterium , for example Mycobacterium tuberculosis, Mycobacterium leprae or Mycobacterium lepromatosis .
- treatment refers to partial or complete alleviation, amelioration, relief, inhibition, delaying onset, or reducing severity and/or incidence of the disease, disorder, or condition in the patient.
- a method for the treatment of an infection with Mycobacterium tuberculosis in a subject comprising administering a therapeutically effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or a pharmaceutically acceptable salt, prodrug, or ester thereof, optionally in a pharmaceutically acceptable carrier to form a pharmaceutical composition.
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula I:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula II:
- the compound of Formula II as used in the methods described herein is a compound of Formula II-a:
- the compound of Formula II as used in the method described herein is a compound of Formula II-b:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula III:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula IV:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula V:
- the compound of Formula V as used herein is a compound of Formula V-a:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula VI:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula VII:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula VIII:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula IX:
- a method for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula X:
- a method for the treatment of an infection caused by Mycobacterium leprae or Mycobacterium lepromatosis in a subject comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or pharmaceutically acceptable salts, prodrugs, or esters thereof.
- a method for the treatment of leprosy in a subject comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or pharmaceutically acceptable salts, prodrugs, or esters thereof.
- a method for the killing of Mycobacterium cells comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- a method for the killing of Mycobacterium tuberculosis cells comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- a method for inhibiting the growth of Mycobacterium cells comprising administering an effective amount one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- Mycobacterium that may be treated by the methods described herein include, but are not limited to: M. africanum, M. bovis, M. bovis BCG, M. canetti, M. caprae, M. microti, M. mungi, M. oryngis, M. pinnipedii, M. suricattae, M. tuberculosis, M. avium, M. avium paratuberculosis, M. avium silvaticum, M. avium “hominissuis”, M. colombiense, M. indicus pranii, M. intracellulare, M. asiatium, M. gordonae, M. gastri, M.
- kansasii M. hiberniae, M. icosiumassiliensis, M. nonchromogenicum, M. terrae, M. trivale, M. ulcerans, M. pseudoshottsii, M. shottsii, M. florentinum, M. genavense, M. heidelbergense, M. interjectum, M. kubicae, M. lentiflavum, M. montefiorense, M. palustre, M. parascrofulaceum, M. simiae, M. triplex, M. arabiense, M. aromaticivorans, M. aquaticum, M. bacteremicum, M. bohemicum, M.
- M. botniense M. branderi, M. celatum, M. chimaera, M. conspicuum, M. cookii, M. doricum, M. farcinogenes, M. haemophilum, M. homeeshornense, M. intracellulare, M. lacus, M. leprae, M. lepromatosis, M. liflandii, M. llatzerense, M. malmoense, M. marinum, M. neoaurum, M. monacense, M. murale, M. nebraskense, M. saskatchewanense, M. sediminis, M. scrofulaceum, M. shimoidei, M.
- aubagnese M. mucogenium, M. phocaicum, M. austroafricanum, M. diernhoferi, M. frederiksbergense, M. hodleri, M. neoaurum, M. parafortuitum, M. aurum, M. vaccae, M. chitae, M. fallax, M. agri, M. aicheinse, M. alvei, M. arupense, M. barrassiae, M. brumae, M. canariasense, M. chubuense, M. conceptionense, M. confulentis, M. duvalii, M. elephantis, M. flavascens, M.
- a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof is provided for the treatment of infection caused by a Mycobacterium .
- a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof is provided for the treatment of tuberculosis in a subject.
- a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof is provided for the treatment of leprosy in a subject.
- use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in an effective amount in the treatment of a subject with a Mycobacterium infection is provided.
- use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in an effective amount in the treatment of a subject with tuberculosis is provided.
- use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of a Mycobacterium infection in a subject is provided.
- use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of a Mycobacterium infection in a subject is provided.
- use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of tuberculosis in a subject is provided.
- use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of leprosy in a subject is provided.
- the present disclosure also includes compounds as used in the methods herein with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched.
- isotopes examples include isotopes of hydrogen, carbon, nitrogen, oxygen, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 15 N, 17 O, 18 O, and 36 Cl, respectively.
- isotopically labeled compounds can be used in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug and substrate tissue distribution assays, or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- an 18 F labeled compound may be particularly desirable for PET or SPECT studies.
- Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed herein by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- isotopes of hydrogen for example deuterium ( 2 H) and tritium ( 3 H) may optionally be used anywhere in described structures that achieves the desired result.
- isotopes of carbon e.g., 13 C and 14 C, may be used.
- the isotopic substitution is replacing hydrogen with a deuterium at one or more locations on the molecule to improve the performance of the molecule as a drug, for example, the pharmacodynamics, pharmacokinetics, biodistribution, half-life, stability, AUC, Tmax, Cmax, etc.
- the deuterium can be bound to carbon in allocation of bond breakage during metabolism (an alpha-deuterium kinetic isotope effect) or next to or near the site of bond breakage (a beta-deuterium kinetic isotope effect).
- Isotopic substitutions for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium.
- the isotope is 80, 85, 90, 95, or 99% or more enriched in an isotope at any location of interest.
- deuterium is 80, 85, 90, 95, or 99% enriched at a desired location. Unless otherwise stated, the enrichment at any point is above natural abundance, and in an embodiment is enough to alter a detectable property of the compounds as a drug in a human.
- solvate refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules.
- solvents are water, ethanol, dimethyl sulfoxide, acetone and other common organic solvents.
- hydrate refers to a molecular complex comprising a disclosed compound and water.
- Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g., D 2 O, d6-acetone, or d6-DMSO.
- a solvate can be in a liquid or solid form.
- a “prodrug” as used herein means a compound which when administered to a host in vivo is converted into a parent drug.
- the term “parent drug” means any of the presently described compounds herein.
- Prodrugs can be used to achieve any desired effect, including to enhance properties of the parent drug or to improve the pharmaceutic or pharmacokinetic properties of the parent, including to increase the half-life of the drug in vivo.
- Prodrug strategies provide choices in modulating the conditions for in vivo generation of the parent drug.
- Non-limiting examples of prodrug strategies include covalent attachment of removable groups, or removable portions of groups, for example, but not limited to, acylating, phosphorylation, phosphonylation, phosphoramidate derivatives, amidation, reduction, oxidation, esterification, alkylation, other carboxy derivatives, sulfoxy or sulfone derivatives, carbonylation, or anhydrides, among others.
- the prodrug renders the parent compound more lipophilic.
- a prodrug can be provided that has several prodrug moieties in a linear, branched, or cyclic manner.
- non-limiting embodiments include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent compound with another prodrug moiety, and is typically biodegradable in vivo.
- a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent compound with another prodrug moiety, and is typically biodegradable in vivo.
- 2, 3, 4, or 5 prodrug biodegradable moieties are covalently bound in a sequence, branched, or cyclic fashion to the parent compound.
- Non-limiting examples of prodrugs according to the present disclosure are formed with: a carboxylic acid on the parent drug and a hydroxylated prodrug moiety to form an ester; a carboxylic acid on the parent drug and an amine prodrug to form an amide; an amino on the parent drug and a carboxylic acid prodrug moiety to form an amide; an amino on the parent drug and a sulfonic acid to form a sulfonamide; a sulfonic acid on the parent drug and an amino on the prodrug moiety to form a sulfonamide; a hydroxyl group on the parent drug and a carboxylic acid on the prodrug moiety to form an ester; a hydroxyl on the parent drug and a hydroxylated prodrug moiety to form an ester; a phosphonate on the parent drug and a hydroxylated prodrug moiety to form a phosphonate ester; a phosphoric acid on the parent drug and a
- a prodrug is provided by attaching a natural or non-natural amino acid to an appropriate functional moiety on the parent compound, for example, oxygen, nitrogen, or sulfur, and typically oxygen or nitrogen, usually in a manner such that the amino acid is cleaved in vivo to provide the parent drug.
- the amino acid can be used alone or covalently linked (straight, branched or cyclic) to one or more other prodrug moieties to modify the parent drug to achieve the desired performance, such as increased half-life, lipophilicity, or other drug delivery or pharmacokinetic properties.
- the amino acid can be any compound with an amino group and a carboxylic acid, which includes an aliphatic amino acid, alkyl amino acid, aromatic amino acid, heteroaliphatic amino acid, heteroalkyl amino acid, heterocyclic amino acid, or heteroaryl amino acid.
- the compounds as used in the methods described herein can be administered in combination with other therapies.
- the compounds described herein can be administered simultaneously, sequentially, or at distinct time points as part of the same therapeutic regimen.
- the compounds as used in the methods described herein may be administered in combination or alternation with a nucleic acid inhibitor.
- the compounds as used in the methods described herein may be administered in combination or alternation with a rifamycin, for example rifampicin, rifabutin, rifapentine, rifalazil, or combinations thereof.
- the compounds as used in the methods described herein may be administered in combination or alternation with an antifolate or a dihydropteroate synthase inhibitor, for example dapsone, acedapsone, aldesulfone sodium, or combinations thereof.
- the compounds as used in the methods described herein may be administered in combination or alternation with 4-aminosalicyclic acid or a salt thereof, for example calcium aminosalicylate or sodium aminosalicylate.
- the compounds as used in the methods described herein may be administered in combination with a quinolone antibiotic, for example gatifloxacin, moxifloxacin, or combinations thereof.
- the compounds as used in the methods described herein may be administered in combination or alternation with a protein synthesis inhibitor. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an aminoglycoside, for example amikacin, kanamycin, streptomycin, or combinations thereof. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an oxazolidinone antibiotic, for example linezolid or serzolid. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a polypeptide antibiotic, for example capreomycin.
- the compounds as used in the methods described herein may be administered in combination or alternation with a cell envelope antibiotic. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with cycloserine. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an antibiotic effective on the peptidoglycan layer, for example cycloserine. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a compound effective on the arabinogalactan layer, for example an ethylenediamine/arabinosyltransferase inhibitor such as ethambutol, or SQ109.
- a compound effective on the arabinogalactan layer for example an ethylenediamine/arabinosyltransferase inhibitor such as ethambutol, or SQ109.
- the compounds as used in the methods described herein may be administered in combination or alternation with an antibiotic effective on the mycolic acid layer, for example hydrazides/mycolic acid synthase inhibitors such as isoniazid and methaniazide, thiocarbamides such as ethionamide, prothionamide, and thiocarlide, and thioacetazone.
- an antibiotic effective on the mycolic acid layer for example hydrazides/mycolic acid synthase inhibitors such as isoniazid and methaniazide, thiocarbamides such as ethionamide, prothionamide, and thiocarlide, and thioacetazone.
- the compounds as used in the methods described herein may be administered in combination or alternation with phenazide, pyrazine, isoxazole, bedaquiline, and metronidazole.
- the compounds as used in the tuberculosis treatment methods described herein may be administered in combination or alternation with ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, or combinations thereof.
- the compounds as used in the tuberculosis treatment methods described herein may be administered in combination or alternation with aminoglycoside antibiotics (e.g., amikacin or kanamycin), polypeptide antibiotics (e.g., capreomycin, viomycin, of enviomycin), fluorquinolones (e.g., ciprofloxacin, levofloxacin, or moxifloxacin), thioamides (e.g., ethionamide or prothionamide), cycloserine, terizidone, or combinations thereof.
- aminoglycoside antibiotics e.g., amikacin or kanamycin
- polypeptide antibiotics e.g., capreomycin, viomycin, of enviomycin
- fluorquinolones e.g., ciprofloxacin, levofloxacin, or moxifloxacin
- thioamides e.g., ethi
- the compounds as used in the tuberculosis treatment methods described herein may be administered in combination or alternation with rifabutin, macrolide antibiotics (e.g., clarithromycin), linezolid, thiacetazone, thioridazine, arginine, vitamin D, or bedaquiline.
- macrolide antibiotics e.g., clarithromycin
- the compounds as used in the leprosy treatment methods described herein may be administered in combination or alternation with acedapsone, clofazimine, dapsone, desoxyfructo-serotonin, diucifon, ethionamide, rifampicin, rifapentine, sulfameter, thalidomide, or combinations thereof.
- the compounds as used in the methods described herein can be administered by any suitable method and technique presently or prospectively known to those skilled in the art.
- the active components described herein can be formulated in a physiologically- or pharmaceutically-acceptable form and administered by any suitable route known in the art including, for example, oral and parenteral routes of administering.
- parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraperitoneal, and intrasternal administration, such as by injection.
- Administration of the active components of their compositions can be a single administration, or at continuous and distinct intervals as can be readily determined by a person skilled in the art.
- compositions comprising an active compound and an excipient of some sort may be useful in a variety of medical and non-medical applications.
- pharmaceutical compositions comprising an active compound and an excipient may be useful for the treatment or prevention of an infection with a Mycobacterium.
- Excipients include any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- General considerations in formulation and/or manufacture can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
- excipients include, but are not limited to, any non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- materials which can serve as excipients include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydro
- the excipients may be chosen based on what the composition is useful for.
- the choice of the excipient will depend on the route of administration, the agent being delivered, time course of delivery of the agent, etc., and can be administered to humans and/or to animals, orally, rectally, parenterally, intracisternally, intravaginally, intranasally, intraperitoneally, topically (as by powders, creams, ointments, or drops), buccally, or as an oral or nasal spray.
- the active compounds disclosed herein are administered topically.
- Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
- Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
- cross-linked poly(vinyl-pyrrolidone) crospovidone
- sodium carboxymethyl starch sodium starch glycolate
- Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g.
- stearyl alcohol cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol
- carbomers e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer
- carrageenan cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g.
- Cremophor polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
- Exemplary binding agents include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g.
- natural and synthetic gums e.g. acacia, sodium alginate, extract of Irish moss, panwar
- Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
- antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
- Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof.
- EDTA ethylenediaminetetraacetic acid
- salts and hydrates thereof e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like
- citric acid and salts and hydrates thereof e.g., citric acid mono
- antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
- antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
- Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
- Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
- Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl.
- the preservative is an anti-oxidant.
- the preservative is a chelating agent.
- Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer
- Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
- Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus , evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba , macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea
- Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.
- composition may further comprise a polymer.
- exemplary polymers contemplated herein include, but are not limited to, cellulosic polymers and copolymers, for example, cellulose ethers such as methylcellulose (MC), hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), methylhydroxyethylcellulose (MHEC), methylhydroxypropylcellulose (MHPC), carboxymethyl cellulose (CMC) and its various salts, including, e.g., the sodium salt, hydroxyethylcarboxymethylcellulose (HECMC) and its various salts, carboxymethylhydroxyethylcellulose (CMHEC) and its various salts, other polysaccharides and polysaccharide derivatives such as starch, dextran, dextran derivatives, chitosan, and alginic acid and its various salts, carageenan, various gums, including xanthan gum, guar gum, gum arab
- composition may further comprise an emulsifying agent.
- emulsifying agents include, but are not limited to, a polyethylene glycol (PEG), a polypropylene glycol, a polyvinyl alcohol, a poly-N-vinyl pyrrolidone and copolymers thereof, poloxamer nonionic surfactants, neutral water-soluble polysaccharides (e.g., dextran, Ficoll, celluloses), non-cationic poly(meth)acrylates, non-cationic polyacrylates, such as poly (meth) acrylic acid, and esters amide and hydroxy alkyl amides thereof, natural emulsifiers (e.g.
- acacia agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g.
- carboxy polymethylene polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer
- carrageenan cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g.
- Cremophor polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
- the emulsifying agent is cholesterol.
- Liquid compositions include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
- the liquid composition may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending
- injectable compositions for example, injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents for pharmaceutical or cosmetic compositions that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium. Any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- the particles are suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1% (v/v) Tween 80.
- the injectable composition can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- compositions for rectal or vaginal administration may be in the form of suppositories which can be prepared by mixing the particles with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.
- Solid compositions include capsules, tablets, pills, powders, and granules.
- the particles are mixed with at least one excipient and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay,
- the dosage form may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- Tablets, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- compositions for topical or transdermal administration include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches.
- the active compound is admixed with an excipient and any needed preservatives or buffers as may be required.
- the ointments, pastes, creams, and gels may contain, in addition to the active compound, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to the active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
- Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
- dosage forms can be made by dissolving or dispensing the nanoparticles in a proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin.
- the rate can be controlled by either providing a rate controlling membrane or by dispersing the particles in a polymer matrix or gel.
- the active ingredient may be administered in such amounts, time, and route deemed necessary in order to achieve the desired result.
- the exact amount of the active ingredient will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular active ingredient, its mode of administration, its mode of activity, and the like.
- the active ingredient, whether the active compound itself, or the active compound in combination with an agent, is preferably formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the active ingredient will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
- the active ingredient may be administered by any route.
- the active ingredient is administered via a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
- routes including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual;
- the most appropriate route of administration will depend upon a variety of factors including the nature of the active ingredient (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration), etc.
- an active ingredient required to achieve a therapeutically or prophylactically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like.
- the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
- Useful dosages of the active agents and pharmaceutical compositions disclosed herein can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art.
- the dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the symptoms or disorder are affected.
- the dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like.
- the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art.
- the dosage can be adjusted by the individual physician in the event of any counterindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.
- Tuberculosis caused by bacterium Mycobacterium tuberculosis , is a worldwide leading cause of death, resulting in 10 million cases globally in 2017 and more than 2 million deaths every year. 1,2,3 At the same time, latent TB infection is also counted in global tuberculosis epidemic. Around 1.7 billion people have latent infection from TB, while some of them may turn to active TB. For example, HIV positive patients have high risk of processing latent to active TB. 4 The conventional treatments for TB are unsatisfying because of low compliance and high costs. 5 Moreover, treatments are required for more complicated situations, such as the emergence of multidrug-resistant tuberculosis (MDR-TB).
- MDR-TB multidrug-resistant tuberculosis
- Mangroves mainly can be found in the intertidal zone in the tropical and subtropical regions. In Florida, there are three mangrove species constituting the coastal ecosystem, including the Red Mangrove ( Rhizophora mangle ), Black Mangrove ( Avicennia germinans ) and White Mangrove ( Laguncularia racemosa ). Mangroves are considered transition zone between terrestrial and marine habitats, which makes the interface capable of having marine and terrestrial fungi co-existing. 8
- Mangrove fungi form the second largest ecological group of the marine fungi. Exposure to higher salt concentration makes the marine fungal growth conditions significantly harsh, which leads to potential diversity and bioactivity. Studies of these fungi demonstrated that most of them produce structurally new and bioactive secondary metabolites. 10
- the bioactivities include anti-tumor, anti-biotic, and anti-virus.
- Zhang, Niaz and Khan reported the isolation of two new sesquiterpenes microsphaeropsisin B and C, and two new de-O-methyllasiodiplodins, (3R,7R)-7-hydroxy-de-o-methyllasiodiplodin and (3R)-5-oxo-de-o-methyllasiodiplodin, along with a new natural product (3R)-7-oxo-de-O-methyllasiodiplodin, from the co-cultivation of a mangrove endophytic fungus Trichoderma sp. 307 and an aquatic pathogenic bacterium Acinetobacter johnsonii B2.
- Microorganisms including fungi, produce diverse metabolites with a range of bioactivities that could be applied as the treatment of infectious diseases, different types of cancer, etc.
- BGC biosynthetic gene clusters
- 14 Activation of cryptic and silent genes would reveal the great potential of microorganisms producing more specialized metabolites.
- Recently, more genomes have been sequenced, inspiring new approaches to explore novel microbial natural products.
- Epigenetic modification is one of the developing methods. It can be only applied for eukaryotic gene expression since it is based on DNA and chromatin, which makes processes such as histone deacetylation and DNA methylation as a means to enhance expression.
- Mangrove forests offer a diverse environment for the endophytic fungi to produce potential bioactive metabolites. It has been proved that mangrove endophytes have the potential to produce bioactive metabolites.
- Floridian mangroves have not been well-studied compared to the mangroves from other areas, for example Asia.
- epigenetic modification is a tool to access potential bioactive compounds that are not translated and produced in regular growth conditions. Our goal is to discover new bioactive fungal metabolites against TB, with application of the epigenetic modification method.
- Mangrove tissues were collected from different environments within Florida, covering various microclimates. Collections sites include Courtney Campbell Causeway, Miami, Fla. (CC); Coquina Beach, Sarasota, Fla. (CQ); Everglades City, Fla. (EG); Howard Frankland Bridge, Tampa, Fla. (HF); and Keys Marine Lab, Layton, Fla. (KML)).
- HTS High-throughput screening
- Mycobacterium tuberculosis the ESKAPE panel of bacterial pathogens, Leishmania donovani and Naegleria fowleri was carried out for almost 2700 fungal strains isolated from mangrove collections.
- Dr. Kyle Rohde's lab in University of Central Florida (UCF) was carrying out the bioassay test against Mycobacterium tuberculosis .
- UCF University of Central Florida
- 8000 fungal extracts were produced and screened for their bioactivity.
- 71 were specifically targeted to Mycobacterium tuberculosis (Mtb). 17
- Fungal strain EG12-25A-3 was inoculated in a larger scale of rice media with 5-azacytidine (DNMT inhibitor) broth (labeled as EG12-25A-3-DNMT) and was cultivated for 21 days. At the same time, the fungal strain sample was sent for identification, and the Shaw lab confirmed this strain is Penicillium sclerotiorum by processing the raw FASTA nucleotide sequence and BLASTn. Cultivation was followed by one period of 24-hour extraction in methanol (MeOH) to ethyl acetate (EtOAc) 1:3, and two periods of 24-hour extraction in EtOAc.
- MeOH methanol
- EtOAc ethyl acetate
- the crude extract was partitioned between hexanes and 70% aqueous MeOH first, followed by the 70% aqueous methanol layer partitioned between EtOAc and water.
- the EtOAc layer was dried and treated with silica, with ratio of mass 1:3.
- Medium pressure liquid chromatography (MPLC) was carried out to fractionate the EtOAc layer, yielding 20 fractions ( FIG. 2 ).
- the MPLC fractions of the EtOAc layer, along with the hexane layer and the water layer from the previous partition process, were tested against replicating stage M. tuberculosis (Mtb), the murine macrophage cell line J774 and M. abscessus (Mab).
- BFY-3 (fraction K-4-1) was isolated as a bright yellow oil, and was found to have the molecular formula of C 21 H 29 ClO 8 , based on HRESIMS (m/z 445.1514 [M+H] + , calculated 445.1585).
- the intensity ratio of peak m/z 445.1514 and peak m/z 447.1642 is 3:1 indicating the presence of one chlorine atom.
- Structure elucidation was completed with 1D and 2D NMR spectroscopy, including 1 H, 13 C, gCOSY, gHSQC and gHMBC spectra. 1D NMR data of BFY3 is shown in Table 2.
- the 1 H NMR spectrum combined with the gHSQC spectrum suggested the presence of five methyls ( ⁇ H 2.04, 1.62, 1.33, 0.89, and 0.85), two methylenes with diastereotopic protons ( ⁇ H 4.25, 3.98, 1.42 and 1.29), three olefinic protons ( ⁇ H 6.78, 6.30 and 6.07), and three methines ( ⁇ H 5.30, 3.44 and 1.72).
- the 13 C NMR spectrum and the gHSQC spectrum indicated the presence of two carbonyl groups ( ⁇ c 193.8 and 172.3), six olefinic carbons (6c 162.3, 146.0, 145.6, 122.5, 120.4 and 101.7), and six oxygenated carbons (6c 81.1, 79.2, 77.0, 73.8, 68.4, 68.3).
- Four exchangeable protons were revealed by the 1 H NMR spectrum in DMSO-d 6 .
- BFY-3 was determined to be a bicyclic compound with 2 carbonyl groups and six olefinic carbons.
- 1 H- 1 H COSY correlations H-13/H 3 -17; H-10/H-9) combined with 2D gHMBC correlations (H 3 -15/C-13 and C-14; H 2 -14/C-12, C-13 and C-15; H 3 -17/C-12, C-13 and C-14; and H-12/C-10, C-11 and C-17) indicated a chain with C-11, C-12, C-13, C-14 and C-15 ( FIG. 4 ), while C-17 was found to connect with C-13.
- One of the two open valances on C-11 was assigned to the methyl group C-16, based on gHMBC correlation H-12/C-16. Further connection was built based on gHMBC correlations H-10/C-3, C-9, C-11 and C-16; H-9/C-3, C-4a, C-4, and C-11; H-4/C-3, C-5 and C-8a, which suggested a conjugated system with three olefins, containing C-10, C-9, C-3, C-4, C-4a and C-5. C-10 was found attached to C-11 based on gHMBC correlation H-10/C-16. 1 H- 1 H COSY correlation between H-9 and H-10 supported the position of C-9 and C-10.
- H 2 -1 has correlations to C-3, C-4a and quaternary carbon C-8a.
- C-1 ⁇ c 73.6
- a six-member ring was built with C-1, C-3, C-4, C-4a, C-8a and an oxygen.
- gHMBC correlation of H-8/C-1, C-4a and C-6 indicated the methine group C-8 is attached to the six-member ring. Further connection was built based on gHMBC correlations H-8/C-18, C-6; H 3 -18/C-6, C-8.
- J-3, K-5-1, and I-7-4 were analyzed based on comparing 1D NMR data with the literature, along with analyzing HESIMS data. These three compounds were identified as possible isomers, based on the same molecular mass. Their NMR data matched with two known compounds eupenicilazaphilone C and hypocrellone A, 18 based on coupling constants related of the chiral centers. The major difference between J-3 and K-5-1 focused on the coupling constant between H-8 and H-8a.
- L-8-4-8 has an acetyl methyl group with a ⁇ H 2.20 in CD 3 OD. Further comparison of the NMR spectrum indicated L-8-4-8 matched with that of geumsanol D (2.26), including chemical shifts and coupling constants. L-8-4-8 was identified as geumsanol D or its isomer. 19 The 1D NMR data is shown in Table 5.
- Fraction M-8-13-5 was isolated as a dark red solid. After comparing 1D NMR data with the literature, M-8-13-5 matched with a known compound isochromophilone IX, which indicated the compound M-8-13-5 is same or an isomer of isochromophilone IX. Isochromophione IX was first isolated in 2003 and showed inhibition against MRSA with MIC of 50 ⁇ g/mL. 20 Comparison of 1D NMR data between M-8-13-5 and isochromophilone IX is shown in Table 7.
- Fraction F-8-3 was eluted from reverse phase with methanol and water, and it was crystallized. Further data collected by X-ray crystallography indicated F-8-3 is a known compound 4-hydroxy-6-methoxy-5-methyl-1(3H)-isobenzofuranone. 23 1 H NMR data was not able to obtain resulting from limited mass.
- fraction G-4 The major compound from this fungal extract was isolated from fraction G.
- the fraction G-4 (was recrystallized as snow-flake shape.
- the structure was identified by X-ray crystallography as pencolide, a well-studied fungal metabolite since 1963. 24 It was reported to show inhibition to S. pyogenes, S. aureus, S. typhimurium E. coli and C. albicans.
- 24 1 D NMR data is shown in Table 9. Comparing to the literature data of pencolide, G-4 matched with pencolide with chemical shift and coupling constants.
- isochromophilone VI is the first naturally occurring nitrogen-containing azaphilone derivative that is reported with antimycobacterial activity.
- compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims and any compositions and methods that are functionally equivalent are intended to fall within the scope of the claims.
- Various modifications of the compositions and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims the benefit of priority to U.S. Provisional Application No. 63/051,476, filed Jul. 14, 2020, the disclosure of which is incorporated herein by reference in its entirety.
- This invention was made with government support under Grant Nos. AI103673 and AI103715 awarded by the National Institute of Allergy and Infection Diseases of the National Institute of Health. The government has certain rights in the invention.
- The present disclosure is directed to methods for treating Mycobacterium infections such as tuberculosis or leprosy.
- Tuberculosis is a common and often deadly infectious caused by Mycobacterium tuberculosis bacteria. Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections are latent (i.e. do not have symptoms), but about 10% of latent tuberculosis infections progress to active disease which can kill about half of those affected if left untreated. The class symptoms of tuberculosis are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. Infection of other organ can lead to a wider range of symptoms.
- Treatment for tuberculosis is difficult, requiring long-term administration of antibiotics. For treatment of active tuberculosis, a patient is typically administered isoniazid (with pyridoxal phosphate), rifampin, pyrazinamide, and ethambutol daily for two months, followed by administration of isoniazid and rifampin daily for a further four months. For latent tuberculosis, the standard treatment is administration of isoniazid alone for three months or three months of weekly isoniazide/rifapentine combination therapy. Antibiotic resistance is a growing problem for tuberculosis, with treatment regimens for resistant strains requiring the administration of stronger drugs over longer time periods. Some strains of tuberculosis are completely resistant to all currently used drugs.
- Thus, there is a clear need for new therapeutic methods for the treatment of Mycobacterium infections.
- In accordance with the purposes of the disclosed materials and methods, as embodied and broadly described herein, the disclosed subject matter, in one aspect, relates to methods for the treatment of infections and other disorders caused by Mycobacterium, for example tuberculosis or leprosy.
- Thus, in one aspect, a method of treating an infection with a Mycobacterium in a subject is provided comprising administering a therapeutically effective amount of one or more compounds selected from:
- or pharmaceutically acceptable salts thereof, prodrugs, or esters thereof.
- In some embodiments, the one or more compounds, or pharmaceutically acceptable salts, prodrugs, or esters thereof, are administered in combination with a pharmaceutically acceptable carrier to form a pharmaceutical composition.
- In some embodiments, the infection comprises tuberculosis. In some embodiments, the infection is caused by Mycobacterium africanum, Mycobacterium bovis, Mycobacterium canetti, Mycobacterium caprae, Mycobacterium microti, Mycobacterium mungi, Mycobacterium orygis, Mycobacterium pinnipedii, Mycobacterium suricattae, or Mycobacterium tuberculosis.
- In some embodiments, the infection comprises leprosy. In some embodiments, the infection is caused by Mycobacterium leprae or Mycobacterium lepromatosis.
- In some embodiments, the infection is caused by Mycobacterium avium, Mycobacterium avium paratuberculosis, Mycobacterium avium silvaticum, Mycobacterium avium hominissuis, Mycobacterium colombiense, Mycobacterium indicus pranii, Mycobacterium intracellulare, Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum, mycobacterium terrae, Mycobacterium xenopi, and Mycobacterium simiae.
- In some embodiments, the one or more compounds are administered in combination or alternation with one or more additional therapeutic agents, for example ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, acedapsone, clofazimine, dapsone, desoxyfructo-serotonin, ethionamide, rifapentine, sulfameter, thalidomide, or combinations thereof.
- In some embodiments, the subject is a human.
- In another aspect, a method for killing one or more Mycobacterium cells is provided comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In yet another aspect, a method for inhibiting the growth of one or more Mycobacterium cells is provided comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- Additional advantages will be set forth in the description that follows, and in part will be obvious from the description, or may be learned by practice of the aspects described below. The advantages described below will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. The foregoing and other features will be come apparent from the following detailed description of several embodiments which proceed with reference to the accompanying drawings.
-
FIG. 1 shows an isolation plate for fungal strain EG12-25A-3 as further described in the examples. -
FIG. 2 shows THE separation scheme for EG12-25A-3-DNMT as further described in the examples. -
FIG. 3 shows the isolation scheme for BFY3 as further described in the examples. -
FIG. 4 shows the key COSY (bolded lines) and HMBC (black arrows) of BFY-3. -
FIG. 5 shows the isolating scheme for BFY4 as further described in the examples. -
FIG. 6 shows the x-ray crystallography structure of BFY-4. -
FIG. 7 shows the x-ray crystallography structure of Fraction D. -
FIG. 8 shows the x-ray crystallography structure of Fraction O-7. -
FIG. 9 shows the x-ray crystallography structure of Fraction F-8-3. -
FIG. 10 shows the x-ray crystallography structure of Fraction G-4. -
FIG. 11 shows the bioactivity and cytotoxicity of Fraction O-7 obtained as further described in the examples. - The following description of the disclosure is provided as an enable teaching of the disclosure in its best, currently known embodiments. To this end, those skilled in the relevant art will recognize and appreciate that many changes can be made to the various embodiments of the invention described herein, while still obtaining the beneficial results of the present disclosure. It will also be apparent that some of the desired benefits of the present disclosure can be obtained by selecting some of the features of the present disclosure without utilizing other features. Accordingly, those who work in the art will recognize that many modifications and adaptations to the present disclosure are possible and can even be desirable in certain circumstances and are part of the present disclosure. Thus, the following description is provided as illustrative of the principles of the present disclosure and not in limitation thereof.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. The following definitions are provided for the full understanding of terms used in the specification.
- As used in the specification and claims, the singular form “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, the term “an agent” includes a plurality of agents, including mixtures thereof.
- As used herein, the terms “may,” “optionally,” and “may optionally” are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation “may include an excipient” is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.
- Administration” to a subject includes any route of introducing or delivering to a subject an agent. Administration can be carried out by any suitable route, including oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques), and the like. “Concurrent administration”, “administration in combination”, “simultaneous administration” or “administered simultaneously” as used herein, means that the compounds are administered at the same point in time or essentially immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time. “Systemic administration” refers to the introducing or delivering to a subject an agent via a route which introduces or delivers the agent to extensive areas of the subject's body (e.g. greater than 50% of the body), for example through entrance into the circulatory or lymph systems. By contrast, “local administration” refers to the introducing or delivery to a subject an agent via a route which introduces or delivers the agent to the area or area immediately adjacent to the point of administration and does not introduce the agent systemically in a therapeutically significant amount. For example, locally administered agents are easily detectable in the local vicinity of the point of administration but are undetectable or detectable at negligible amounts in distal parts of the subject's body. Administration includes self-administration and the administration by another.
- As used here, the terms “beneficial agent” and “active agent” are used interchangeably herein to refer to a chemical compound or composition that has a beneficial biological effect. Beneficial biological effects include both therapeutic effects, i.e., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, i.e., prevention of a disorder or other undesirable physiological condition. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, and the like. When the terms “beneficial agent” or “active agent” are used, then, or when a particular agent is specifically identified, it is to be understood that the term includes the agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, conjugates, active metabolites, isomers, fragments, analogs, etc.
- As used herein, the terms “treating” or “treatment” of a subject includes the administration of a drug to a subject with the purpose of preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder. The terms “treating” and “treatment” can also refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage.
- As used herein, the term “preventing” a disorder or unwanted physiological event in a subject refers specifically to the prevention of the occurrence of symptoms and/or their underlying cause, wherein the subject may or may not exhibit heightened susceptibility to the disorder or event.
- By the term “effective amount” of a therapeutic agent is meant a nontoxic but sufficient amount of a beneficial agent to provide the desired effect. The amount of beneficial agent that is “effective” will vary from subject to subject, depending on the age and general condition of the subject, the particular beneficial agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount”. However, an appropriate “effective” amount in any subject case may be determined by one of ordinary skill in the art using routine experimentation. Also, as used herein, and unless specifically stated otherwise, an “effective amount” of a beneficial can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.
- An “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- As used herein, a “therapeutically effective amount” of a therapeutic agent refers to an amount that is effective to achieve a desired therapeutic result, and a “prophylactically effective amount” of a therapeutic agent refers to an amount that is effective to prevent an unwanted physiological condition. Therapeutically effective and prophylactically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the subject. The term “therapeutically effective amount” can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect. The precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
- As used herein, the term “pharmaceutically acceptable” component can refer to a component that is not biologically or otherwise undesirable, i.e., the component may be incorporated into a pharmaceutical formulation of the invention and administered to a subject as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained. When the term “pharmaceutically acceptable” is used to refer to an excipient, it is generally implied that the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
- “Pharmaceutically acceptable carrier” (sometimes referred to as a “carrier”) means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and includes a carrier that is acceptable for veterinary and/or human pharmaceutical or therapeutic use. The terms “carrier” or “pharmaceutically acceptable carrier” can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil/water or water/oil emulsion) and/or various types of wetting agents. As used herein, the term “carrier” encompasses, but is not limited to, any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations and as described further herein.
- As used herein, “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, non-toxic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disuifonic, oxalic, isethionic, HOOC—(CH2)n-COOH where n is 0-4, and the like, or using a different acid that produces the same counterion. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
- Also, as used herein, the term “pharmacologically active” (or simply “active”), as in a “pharmacologically active” derivative or analog, can refer to a derivative or analog (e.g., a salt, ester, amide, conjugate, metabolite, isomer, fragment, etc.) having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
- As used herein, the term “subject” or “host” can refer to living organisms such as mammals, including, but not limited to humans, livestock, dogs, cats, and other mammals. Administration of the therapeutic agents can be carried out at dosages and for periods of time effective for treatment of a subject. In some embodiments, the subject is a human.
- The compounds described herein include enantiomers, mixtures of enantiomers, diastereomers, tautomers, racemates and other isomers, such as rotamers, as if each is specifically described, unless otherwise indicated or otherwise excluded by context. It is to be understood that the compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R-) or (S-) configuration. The compounds provided herein may either be enantiomerically pure, or be diastereomeric or enantiomeric mixtures. It is to be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo. As such, one of skill in the art will recognize that administration of a compound in its (R-) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S-) form. Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g., each enantiomer, diastereomer, and meso compound, and a mixture of isomers, such as a racemic or scalemic mixture.
- Reference will now be made in detail to specific aspects of the disclosed materials, compounds, compositions, and methods, examples of which are illustrated in the accompanying Examples and Figures.
- As discussed above, the compounds described herein can be used to treat or prevent a disease, disorder, or condition in a patient in need thereof that is the result of an infection by a Mycobacterium, for example Mycobacterium tuberculosis, Mycobacterium leprae or Mycobacterium lepromatosis. In some embodiments, treatment refers to partial or complete alleviation, amelioration, relief, inhibition, delaying onset, or reducing severity and/or incidence of the disease, disorder, or condition in the patient.
- Disclosed herein are methods of treating an infection with a Mycobacterium in a subject by administering a therapeutically effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or pharmaceutically acceptable salts, prodrugs, or esters thereof, optionally in a pharmaceutically acceptable carrier to form a pharmaceutical composition. In one embodiment, a method for the treatment of an infection with Mycobacterium tuberculosis in a subject is provided comprising administering a therapeutically effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or a pharmaceutically acceptable salt, prodrug, or ester thereof, optionally in a pharmaceutically acceptable carrier to form a pharmaceutical composition.
- In one embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula II:
- Or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In one embodiment, the compound of Formula II as used in the methods described herein is a compound of Formula II-a:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, the compound of Formula II as used in the method described herein is a compound of Formula II-b:
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula III:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula IV:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula V:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In one embodiment, the compound of Formula V as used herein is a compound of Formula V-a:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula VI:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula VII:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula VIII:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula IX:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of tuberculosis in a subject comprising administering an effective amount of a compound of Formula X:
- or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for the treatment of an infection caused by Mycobacterium leprae or Mycobacterium lepromatosis in a subject comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or pharmaceutically acceptable salts, prodrugs, or esters thereof. In another embodiment, a method is provided for the treatment of leprosy in a subject comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or pharmaceutically acceptable salts, prodrugs, or esters thereof.
- In another embodiment, a method is provided for the killing of Mycobacterium cells comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof. In another embodiment, a method is provided for the killing of Mycobacterium tuberculosis cells comprising administering an effective amount of one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- In another embodiment, a method is provided for inhibiting the growth of Mycobacterium cells comprising administering an effective amount one or more compounds selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- Representative examples of Mycobacterium that may be treated by the methods described herein include, but are not limited to: M. africanum, M. bovis, M. bovis BCG, M. canetti, M. caprae, M. microti, M. mungi, M. oryngis, M. pinnipedii, M. suricattae, M. tuberculosis, M. avium, M. avium paratuberculosis, M. avium silvaticum, M. avium “hominissuis”, M. colombiense, M. indicus pranii, M. intracellulare, M. asiatium, M. gordonae, M. gastri, M. kansasii, M. hiberniae, M. icosiumassiliensis, M. nonchromogenicum, M. terrae, M. trivale, M. ulcerans, M. pseudoshottsii, M. shottsii, M. florentinum, M. genavense, M. heidelbergense, M. interjectum, M. kubicae, M. lentiflavum, M. montefiorense, M. palustre, M. parascrofulaceum, M. simiae, M. triplex, M. arabiense, M. aromaticivorans, M. aquaticum, M. bacteremicum, M. bohemicum, M. botniense, M. branderi, M. celatum, M. chimaera, M. conspicuum, M. cookii, M. doricum, M. farcinogenes, M. haemophilum, M. heckeshornense, M. intracellulare, M. lacus, M. leprae, M. lepromatosis, M. liflandii, M. llatzerense, M. malmoense, M. marinum, M. neoaurum, M. monacense, M. murale, M. nebraskense, M. saskatchewanense, M. sediminis, M. scrofulaceum, M. shimoidei, M. szulgai, M. talmoniae, M. tusciae, M. xenopi, M. yongonense, M. intermedium, M. abscessus, M. bolletii, M. massiliense, M. chelonae, M. immunogenum, M. stephanolepidis, M. boenickei, M. brisbanense, M. cosmeticum, M. fortuitum, M. fortuitum subsp. acetamidolyticum, M. houstonense, M. mageritense, M. neworleansense, M. peregrinum, M. porcinum, M. senegalense, M. septicum, M. aubagnese, M. mucogenium, M. phocaicum, M. austroafricanum, M. diernhoferi, M. frederiksbergense, M. hodleri, M. neoaurum, M. parafortuitum, M. aurum, M. vaccae, M. chitae, M. fallax, M. agri, M. aicheinse, M. alvei, M. arupense, M. barrassiae, M. brumae, M. canariasense, M. chubuense, M. conceptionense, M. confulentis, M. duvalii, M. elephantis, M. flavascens, M. gadium, M. gilvum, M. hassiacum, M. holsaticum, M. iranicum, M. komossense, M. madagascariense, M. massilipolynesiensis, M. moriokaense, M. obuense, M. phlei, M. psychrotolerans, M. pulveris, M. pyrenivorans, M. smegmatis, M. goodii, M. wolinskyi, M. sphagni, M. the rmoresistibile, M. vanbaalenii, M. arosiense, M. aubagnense, M. chlorophenolicum, M. fluoroanthenivorans, M. kumamatonense, M. novocastrense, M. parmense, M. poriferae, M. Rhodesia, M. seoulense, and M. tokaiense.
- In another embodiment, a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, is provided for the treatment of infection caused by a Mycobacterium. In another embodiment, a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, is provided for the treatment of tuberculosis in a subject. In another embodiment, a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, is provided for the treatment of leprosy in a subject.
- In another embodiment, use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in an effective amount in the treatment of a subject with a Mycobacterium infection is provided. In another embodiment, use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in an effective amount in the treatment of a subject with tuberculosis is provided. In another embodiment, use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in an effective amount in the treatment of a subject with leprosy is provided.
- In another embodiment, use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of a Mycobacterium infection in a subject is provided. In another embodiment, use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of a Mycobacterium infection in a subject is provided. In another embodiment, use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of tuberculosis in a subject is provided. In another embodiment, use a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, or Formula X, or a pharmaceutically acceptable salt, prodrug, or ester thereof, or combinations thereof, in the manufacture of a medicament for the treatment of leprosy in a subject is provided.
- The present disclosure also includes compounds as used in the methods herein with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched.
- Examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, and chlorine, such as 2H, 3H, 11C, 13C, 15N, 17O, 18O, and 36Cl, respectively. In one embodiment, isotopically labeled compounds can be used in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug and substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed herein by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- By way of general example and without limitation, isotopes of hydrogen, for example deuterium (2H) and tritium (3H) may optionally be used anywhere in described structures that achieves the desired result. Alternatively or in addition, isotopes of carbon, e.g., 13C and 14C, may be used. In one embodiment, the isotopic substitution is replacing hydrogen with a deuterium at one or more locations on the molecule to improve the performance of the molecule as a drug, for example, the pharmacodynamics, pharmacokinetics, biodistribution, half-life, stability, AUC, Tmax, Cmax, etc. For example, the deuterium can be bound to carbon in allocation of bond breakage during metabolism (an alpha-deuterium kinetic isotope effect) or next to or near the site of bond breakage (a beta-deuterium kinetic isotope effect).
- Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain embodiments, the isotope is 80, 85, 90, 95, or 99% or more enriched in an isotope at any location of interest. In some embodiments, deuterium is 80, 85, 90, 95, or 99% enriched at a desired location. Unless otherwise stated, the enrichment at any point is above natural abundance, and in an embodiment is enough to alter a detectable property of the compounds as a drug in a human.
- The compounds as used in the present disclosure may form a solvate with solvents (including water). Therefore, in one embodiment, the invention includes use of a solvated form of the active compound. The term “solvate” refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Non-limiting examples of solvents are water, ethanol, dimethyl sulfoxide, acetone and other common organic solvents. The term “hydrate” refers to a molecular complex comprising a disclosed compound and water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g., D2O, d6-acetone, or d6-DMSO. A solvate can be in a liquid or solid form.
- A “prodrug” as used herein means a compound which when administered to a host in vivo is converted into a parent drug. As used herein, the term “parent drug” means any of the presently described compounds herein. Prodrugs can be used to achieve any desired effect, including to enhance properties of the parent drug or to improve the pharmaceutic or pharmacokinetic properties of the parent, including to increase the half-life of the drug in vivo. Prodrug strategies provide choices in modulating the conditions for in vivo generation of the parent drug. Non-limiting examples of prodrug strategies include covalent attachment of removable groups, or removable portions of groups, for example, but not limited to, acylating, phosphorylation, phosphonylation, phosphoramidate derivatives, amidation, reduction, oxidation, esterification, alkylation, other carboxy derivatives, sulfoxy or sulfone derivatives, carbonylation, or anhydrides, among others. In certain embodiments, the prodrug renders the parent compound more lipophilic. In certain embodiments, a prodrug can be provided that has several prodrug moieties in a linear, branched, or cyclic manner. For example, non-limiting embodiments include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent compound with another prodrug moiety, and is typically biodegradable in vivo. In some embodiments, 2, 3, 4, or 5 prodrug biodegradable moieties are covalently bound in a sequence, branched, or cyclic fashion to the parent compound. Non-limiting examples of prodrugs according to the present disclosure are formed with: a carboxylic acid on the parent drug and a hydroxylated prodrug moiety to form an ester; a carboxylic acid on the parent drug and an amine prodrug to form an amide; an amino on the parent drug and a carboxylic acid prodrug moiety to form an amide; an amino on the parent drug and a sulfonic acid to form a sulfonamide; a sulfonic acid on the parent drug and an amino on the prodrug moiety to form a sulfonamide; a hydroxyl group on the parent drug and a carboxylic acid on the prodrug moiety to form an ester; a hydroxyl on the parent drug and a hydroxylated prodrug moiety to form an ester; a phosphonate on the parent drug and a hydroxylated prodrug moiety to form a phosphonate ester; a phosphoric acid on the parent drug and a hydroxylated prodrug moiety to form a phosphate ester; a hydroxyl on the parent drug and a phosphonate on the prodrug to form a phosphonate ester; a hydroxyl on the parent drug and a phosphoric acid prodrug moiety to form a phosphate ester; a carboxylic acid on the parent drug and a prodrug of the structure HO—(CH2)2—O—(C2-24 alkyl) to form an ester; a carboxylic acid on the parent drug and a prodrug of the structure HO—(CH2)2—S—(C2-24 alkyl) to form a thioester; a hydroxyl on the parent drug and a prodrug of the structure HO—(CH2)2—O—(C2-24 alkyl) to form an ether; a hydroxyl on the parent drug and a prodrug of the structure HO—(CH2)2—O—(C2-24 alkyl) to form an thioether; and a carboxylic acid, oxime, hydrazide, hydrazine, amine or hydroxyl on the parent compound and a prodrug moiety that is a biodegradable polymer or oligomer including but not limited to polylactic acid, polylactide-co-glycolide, polyglycolide, polyethylene glycol, polyanhydride, polyester, polyamide, or a peptide.
- In some embodiments, a prodrug is provided by attaching a natural or non-natural amino acid to an appropriate functional moiety on the parent compound, for example, oxygen, nitrogen, or sulfur, and typically oxygen or nitrogen, usually in a manner such that the amino acid is cleaved in vivo to provide the parent drug. The amino acid can be used alone or covalently linked (straight, branched or cyclic) to one or more other prodrug moieties to modify the parent drug to achieve the desired performance, such as increased half-life, lipophilicity, or other drug delivery or pharmacokinetic properties. The amino acid can be any compound with an amino group and a carboxylic acid, which includes an aliphatic amino acid, alkyl amino acid, aromatic amino acid, heteroaliphatic amino acid, heteroalkyl amino acid, heterocyclic amino acid, or heteroaryl amino acid.
- In some embodiments, the compounds as used in the methods described herein can be administered in combination with other therapies. The compounds described herein can be administered simultaneously, sequentially, or at distinct time points as part of the same therapeutic regimen.
- In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a nucleic acid inhibitor. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a rifamycin, for example rifampicin, rifabutin, rifapentine, rifalazil, or combinations thereof. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an antifolate or a dihydropteroate synthase inhibitor, for example dapsone, acedapsone, aldesulfone sodium, or combinations thereof. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with 4-aminosalicyclic acid or a salt thereof, for example calcium aminosalicylate or sodium aminosalicylate. In some embodiments, the compounds as used in the methods described herein may be administered in combination with a quinolone antibiotic, for example gatifloxacin, moxifloxacin, or combinations thereof.
- In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a protein synthesis inhibitor. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an aminoglycoside, for example amikacin, kanamycin, streptomycin, or combinations thereof. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an oxazolidinone antibiotic, for example linezolid or sutezolid. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a polypeptide antibiotic, for example capreomycin.
- In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a cell envelope antibiotic. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with cycloserine. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an antibiotic effective on the peptidoglycan layer, for example cycloserine. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with a compound effective on the arabinogalactan layer, for example an ethylenediamine/arabinosyltransferase inhibitor such as ethambutol, or SQ109. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with an antibiotic effective on the mycolic acid layer, for example hydrazides/mycolic acid synthase inhibitors such as isoniazid and methaniazide, thiocarbamides such as ethionamide, prothionamide, and thiocarlide, and thioacetazone. In some embodiments, the compounds as used in the methods described herein may be administered in combination or alternation with phenazide, pyrazine, isoxazole, bedaquiline, and metronidazole.
- In some embodiments, the compounds as used in the tuberculosis treatment methods described herein may be administered in combination or alternation with ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, or combinations thereof. In other embodiments, the compounds as used in the tuberculosis treatment methods described herein may be administered in combination or alternation with aminoglycoside antibiotics (e.g., amikacin or kanamycin), polypeptide antibiotics (e.g., capreomycin, viomycin, of enviomycin), fluorquinolones (e.g., ciprofloxacin, levofloxacin, or moxifloxacin), thioamides (e.g., ethionamide or prothionamide), cycloserine, terizidone, or combinations thereof. In other embodiments, the compounds as used in the tuberculosis treatment methods described herein may be administered in combination or alternation with rifabutin, macrolide antibiotics (e.g., clarithromycin), linezolid, thiacetazone, thioridazine, arginine, vitamin D, or bedaquiline.
- In some embodiments, the compounds as used in the leprosy treatment methods described herein may be administered in combination or alternation with acedapsone, clofazimine, dapsone, desoxyfructo-serotonin, diucifon, ethionamide, rifampicin, rifapentine, sulfameter, thalidomide, or combinations thereof.
- The compounds as used in the methods described herein can be administered by any suitable method and technique presently or prospectively known to those skilled in the art. For example, the active components described herein can be formulated in a physiologically- or pharmaceutically-acceptable form and administered by any suitable route known in the art including, for example, oral and parenteral routes of administering. As used herein, the term “parenteral” includes subcutaneous, intradermal, intravenous, intramuscular, intraperitoneal, and intrasternal administration, such as by injection. Administration of the active components of their compositions can be a single administration, or at continuous and distinct intervals as can be readily determined by a person skilled in the art.
- Compositions, as described herein, comprising an active compound and an excipient of some sort may be useful in a variety of medical and non-medical applications. For example, pharmaceutical compositions comprising an active compound and an excipient may be useful for the treatment or prevention of an infection with a Mycobacterium.
- “Excipients” include any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. General considerations in formulation and/or manufacture can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
- Exemplary excipients include, but are not limited to, any non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as excipients include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. As would be appreciated by one of skill in this art, the excipients may be chosen based on what the composition is useful for. For example, with a pharmaceutical composition or cosmetic composition, the choice of the excipient will depend on the route of administration, the agent being delivered, time course of delivery of the agent, etc., and can be administered to humans and/or to animals, orally, rectally, parenterally, intracisternally, intravaginally, intranasally, intraperitoneally, topically (as by powders, creams, ointments, or drops), buccally, or as an oral or nasal spray. In some embodiments, the active compounds disclosed herein are administered topically.
- Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
- Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
- Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myrj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof. Exemplary binding agents include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, etc., and/or combinations thereof.
- Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
- Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
- Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
- Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
- Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
- Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid. Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl. In certain embodiments, the preservative is an anti-oxidant. In other embodiments, the preservative is a chelating agent.
- Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and combinations thereof.
- Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
- Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.
- Additionally, the composition may further comprise a polymer. Exemplary polymers contemplated herein include, but are not limited to, cellulosic polymers and copolymers, for example, cellulose ethers such as methylcellulose (MC), hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), methylhydroxyethylcellulose (MHEC), methylhydroxypropylcellulose (MHPC), carboxymethyl cellulose (CMC) and its various salts, including, e.g., the sodium salt, hydroxyethylcarboxymethylcellulose (HECMC) and its various salts, carboxymethylhydroxyethylcellulose (CMHEC) and its various salts, other polysaccharides and polysaccharide derivatives such as starch, dextran, dextran derivatives, chitosan, and alginic acid and its various salts, carageenan, various gums, including xanthan gum, guar gum, gum arabic, gum karaya, gum ghatti, konjac and gum tragacanth, glycosaminoglycans and proteoglycans such as hyaluronic acid and its salts, proteins such as gelatin, collagen, albumin, and fibrin, other polymers, for example, polyhydroxyacids such as polylactide, polyglycolide, polyl(lactide-co-glycolide) and poly(.epsilon.-caprolactone-co-glycolide)-, carboxyvinyl polymers and their salts (e.g., carbomer), polyvinylpyrrolidone (PVP), polyacrylic acid and its salts, polyacrylamide, polyacrylic acid/acrylamide copolymer, polyalkylene oxides such as polyethylene oxide, polypropylene oxide, poly(ethylene oxide-propylene oxide), and a Pluronic polymer, polyoxy ethylene (polyethylene glycol), polyanhydrides, polyvinylalchol, polyethyleneamine and polypyrridine, polyethylene glycol (PEG) polymers, such as PEGylated lipids (e.g., PEG-stearate, 1,2-Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-1000], 1,2-Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000], and 1,2-Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-5000]), copolymers and salts thereof.
- Additionally, the composition may further comprise an emulsifying agent. Exemplary emulsifying agents include, but are not limited to, a polyethylene glycol (PEG), a polypropylene glycol, a polyvinyl alcohol, a poly-N-vinyl pyrrolidone and copolymers thereof, poloxamer nonionic surfactants, neutral water-soluble polysaccharides (e.g., dextran, Ficoll, celluloses), non-cationic poly(meth)acrylates, non-cationic polyacrylates, such as poly (meth) acrylic acid, and esters amide and hydroxy alkyl amides thereof, natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myrj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof. In certain embodiments, the emulsifying agent is cholesterol.
- Liquid compositions include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid composition may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Injectable compositions, for example, injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents for pharmaceutical or cosmetic compositions that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. In certain embodiments, the particles are suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1% (v/v) Tween 80. The injectable composition can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- Compositions for rectal or vaginal administration may be in the form of suppositories which can be prepared by mixing the particles with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.
- Solid compositions include capsules, tablets, pills, powders, and granules. In such solid compositions, the particles are mixed with at least one excipient and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- Tablets, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- Compositions for topical or transdermal administration include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active compound is admixed with an excipient and any needed preservatives or buffers as may be required.
- The ointments, pastes, creams, and gels may contain, in addition to the active compound, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to the active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
- Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the nanoparticles in a proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the particles in a polymer matrix or gel.
- The active ingredient may be administered in such amounts, time, and route deemed necessary in order to achieve the desired result. The exact amount of the active ingredient will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular active ingredient, its mode of administration, its mode of activity, and the like. The active ingredient, whether the active compound itself, or the active compound in combination with an agent, is preferably formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the active ingredient will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
- The active ingredient may be administered by any route. In some embodiments, the active ingredient is administered via a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the active ingredient (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration), etc.
- The exact amount of an active ingredient required to achieve a therapeutically or prophylactically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
- Useful dosages of the active agents and pharmaceutical compositions disclosed herein can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art.
- The dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the symptoms or disorder are affected. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counterindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.
- A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modification may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
- The following examples are set forth below to illustrate the compounds, compositions, methods, and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present invention which are apparent to one skilled in the art.
- Tuberculosis (TB), caused by bacterium Mycobacterium tuberculosis, is a worldwide leading cause of death, resulting in 10 million cases globally in 2017 and more than 2 million deaths every year.1,2,3 At the same time, latent TB infection is also counted in global tuberculosis epidemic. Around 1.7 billion people have latent infection from TB, while some of them may turn to active TB. For example, HIV positive patients have high risk of processing latent to active TB.4 The conventional treatments for TB are unsatisfying because of low compliance and high costs.5 Moreover, treatments are required for more complicated situations, such as the emergence of multidrug-resistant tuberculosis (MDR-TB). Currently the recommended treatment regimen for MDR-TB by the World Health Organization (WHO) is 9-12 months.6 Newer treatments with shorter treatment regimen and higher efficacy are urgently needed to overcome the challenge created from multidrug-resistant and extensively drug-resistant tuberculosis.7
- Mangroves mainly can be found in the intertidal zone in the tropical and subtropical regions. In Florida, there are three mangrove species constituting the coastal ecosystem, including the Red Mangrove (Rhizophora mangle), Black Mangrove (Avicennia germinans) and White Mangrove (Laguncularia racemosa). Mangroves are considered transition zone between terrestrial and marine habitats, which makes the interface capable of having marine and terrestrial fungi co-existing.8
- Mangrove fungi form the second largest ecological group of the marine fungi. Exposure to higher salt concentration makes the marine fungal growth conditions significantly harsh, which leads to potential diversity and bioactivity. Studies of these fungi demonstrated that most of them produce structurally new and bioactive secondary metabolites.10 The bioactivities include anti-tumor, anti-biotic, and anti-virus.10 For example, Wen isolated a new abscisic acid-type sesquiterpene (1'S, 2Z)-3-Methyl-5-(2,6,6-trimethyl-4-oxocyclohex-2-enyl)pent-2-enoicacid, a new asterric acid derivative methyl 2-(2-carboxy-4-hydroxy-6-methoxylphenoxy)-6-hydroxy-4-methylbenzoate and three known compounds asterric acid, methyl asterrate and methyl 3-chloroasterric acid from mangrove endophytic fungus Pleosporales sp. SK7.11
-
-
- R1═H, R2═CH3, R3═H, methyl 2-(2-carboxy-4-hydroxy-6-methoxylphenoxy)-6-hydroxy-4-methylbenzoate
- R1═CH3, R2═H, R3═H, asterric acid;
- R1═CH3, R2═CH3, R3═H, methyl asterrate;
- R1═CH3, R2═H, R3═C1, methyl 3-chloroasterric acid
- Zhang, Niaz and Khan reported the isolation of two new sesquiterpenes microsphaeropsisin B and C, and two new de-O-methyllasiodiplodins, (3R,7R)-7-hydroxy-de-o-methyllasiodiplodin and (3R)-5-oxo-de-o-methyllasiodiplodin, along with a new natural product (3R)-7-oxo-de-O-methyllasiodiplodin, from the co-cultivation of a mangrove endophytic fungus Trichoderma sp. 307 and an aquatic pathogenic bacterium Acinetobacter johnsonii B2. Among these new secondary metabolites, (3R,7R)-7-hydroxy-de-O-methyllasiodiplodin and (3R)-5-oxo-de-O-methyllasiodiplodin exhibited α-glucosidase inhibition activity with IC50 of 25.8 and 54.6 μM, which is significantly higher than the positive control acarbose with IC50 of 703.8 μM.12
- Ding and his colleagues worked on the marine fungus Penicillium sp. SK5GW1L and isolated a new α-pyrone meroterpenoid, 3-epiarigsugacin E and four known compounds from the same class, arisugacin D, arisugacin B, territrem C and terreulactone C. Arisugacin B, territrem C and terreulactone C exhibited activities against acetylcholinesterase (AchE) with IC50 of 3.03, 0.23 and 0.028 μM.13
- Microorganisms, including fungi, produce diverse metabolites with a range of bioactivities that could be applied as the treatment of infectious diseases, different types of cancer, etc. However, there are many biosynthetic gene clusters (BGC) that stay silent or are expressed at very low levels in standard laboratory growing conditions.14 Activation of cryptic and silent genes would reveal the great potential of microorganisms producing more specialized metabolites. Recently, more genomes have been sequenced, inspiring new approaches to explore novel microbial natural products.15 Epigenetic modification is one of the developing methods. It can be only applied for eukaryotic gene expression since it is based on DNA and chromatin, which makes processes such as histone deacetylation and DNA methylation as a means to enhance expression.
- There is an urgent need for new and effective drugs to treat infectious diseases, including TB. Mangrove forests offer a diverse environment for the endophytic fungi to produce potential bioactive metabolites. It has been proved that mangrove endophytes have the potential to produce bioactive metabolites. However, Floridian mangroves have not been well-studied compared to the mangroves from other areas, for example Asia. At the same time, epigenetic modification is a tool to access potential bioactive compounds that are not translated and produced in regular growth conditions. Our goal is to discover new bioactive fungal metabolites against TB, with application of the epigenetic modification method.
- Mangrove tissues were collected from different environments within Florida, covering various microclimates. Collections sites include Courtney Campbell Causeway, Tampa, Fla. (CC); Coquina Beach, Sarasota, Fla. (CQ); Everglades City, Fla. (EG); Howard Frankland Bridge, Tampa, Fla. (HF); and Keys Marine Lab, Layton, Fla. (KML)).
- High-throughput screening (HTS) against Mycobacterium tuberculosis, the ESKAPE panel of bacterial pathogens, Leishmania donovani and Naegleria fowleri was carried out for almost 2700 fungal strains isolated from mangrove collections. Dr. Kyle Rohde's lab in University of Central Florida (UCF) was carrying out the bioassay test against Mycobacterium tuberculosis. With epigenetic-modulated cultures and non-epigenetic-modulated (control) culture of each fungal strain, 8000 fungal extracts were produced and screened for their bioactivity. Among these extracts, 71 were specifically targeted to Mycobacterium tuberculosis (Mtb).17
- Based on the results from the pilot HTS, fungal strains with significant bioactivity were selected to be cultured on a larger scale. One strain, EG12-25A-3 (EverGlades 2012 colony 25 from isolation plate with media type A (what's in media type A?) and
colony 3 from purification plate) (FIG. 1 ) was prioritized according to its anti-TB bioactivity. It exhibited 85% inhibition activity against M. tuberculosis and 48.2% inhibition activity against non-tuberculosis mycobacterium Mycobacterium abscessus (Mab) in the DNA methyltransferase (DNMT) inhibitor-treated culture. Larger scale cultivation was applied to this fungal strain to produce more extract biomass, followed by chemical investigation. - Fungal strain EG12-25A-3 was inoculated in a larger scale of rice media with 5-azacytidine (DNMT inhibitor) broth (labeled as EG12-25A-3-DNMT) and was cultivated for 21 days. At the same time, the fungal strain sample was sent for identification, and the Shaw lab confirmed this strain is Penicillium sclerotiorum by processing the raw FASTA nucleotide sequence and BLASTn. Cultivation was followed by one period of 24-hour extraction in methanol (MeOH) to ethyl acetate (EtOAc) 1:3, and two periods of 24-hour extraction in EtOAc. The crude extract was partitioned between hexanes and 70% aqueous MeOH first, followed by the 70% aqueous methanol layer partitioned between EtOAc and water. The EtOAc layer was dried and treated with silica, with ratio of mass 1:3. Medium pressure liquid chromatography (MPLC) was carried out to fractionate the EtOAc layer, yielding 20 fractions (
FIG. 2 ). The MPLC fractions of the EtOAc layer, along with the hexane layer and the water layer from the previous partition process, were tested against replicating stage M. tuberculosis (Mtb), the murine macrophage cell line J774 and M. abscessus (Mab). The bioactivity data taken with proton nuclear magnetic resonance (1H NMR) data was used to guide further separation. Table 1. shows the bioassay results. The fractions in the blue rows were considered moderately active against replicating Mtb and Mab, with define cytotoxicity results. The green rows show the fractions with better replicating Mtb bioactivity compared to the blue ones. Active fractions with define peaks in 1H NMR were selected and further separated with high performance liquid chromatography (HPLC). After several rounds of separation with normal phase (NP) HPLC and reverse phase (RP) HPLC, two new compounds (BFY-3 and BFY-4), along with nine known compounds, were isolated from the EG12-25A-3-DNMT extract (FIG. 3 andFIG. 4 ). -
TABLE 1 Bioassay data from hexane, water and EtOAc layers, and MPLC fractions from EG12-25A- 3-DNMT extract. (data from Dr. Kyle Rohde) MIC IC50 M. abscessus (% inhibition) Com- (Mtb-rep) (J774) 300 150 75 37.5 pound (μg/ml) (μg/ml) μg/ml μg/ml μg/ml μg/ml EtOAc-A n/d n/d 0.0 0.0 0.0 0.0 EtOAc-B ~75 ~200 49.5 40.6 30.5 0.0 EtOAc-C ~20 ~100 78.1 79.6 70.7 35.3 EtOAc-D ~10 ~100 62.6 67.2 50.4 0.0 EtOAc-E ~25 ~100 67.7 65.6 56.9 23.3 EtOAc-F ~20 ~50 87.3 82.3 70.3 52.8 EtOAc-G ~15 ~50 92.6 88.0 65.6 58.2 EtOAc-H 12.43 ~25 92.9 89.6 70.7 34.4 EtOAc-I ~40 n/d 89.7 71.1 40.9 4.4 EtOAc-J ~50 n/d 79.7 79.7 61.7 42.6 EtOAc-K ~100 n/d 42.9 31.2 9.9 0.0 EtOAc-L ~100 ~250 46.9 46.7 28.7 0.0 EtOAc-M ~150 n/d 96.1 83.1 62.8 51.3 EtOAc-M ~300 ~300 34.6 35.3 22.1 6.0 EtOAc-O ~50 ~50 101.9 74.4 51.9 43.8 EtOAc-P ~150 ~1 54.3 47.6 14.2 6.4 EtOAc-Q ~200 n/d 82.6 79.4 64.0 28.5 EtOAc-R ~150 n/d 78.2 77.9 62.5 15.4 EtOAc-S ~100 n/d 85.6 74.6 70.4 16.6 EtOAc-T ~100 n/d 76.5 77.3 60.6 7.0 Hexane ~300 ~200 33.9 40.9 32.6 0.0 H2O n/d ~300 18.5 9.2 0.0 0.0 - BFY-3 (fraction K-4-1) was isolated as a bright yellow oil, and was found to have the molecular formula of C21H29ClO8, based on HRESIMS (m/z 445.1514 [M+H]+, calculated 445.1585). The intensity ratio of peak m/z 445.1514 and peak m/z 447.1642 is 3:1 indicating the presence of one chlorine atom. Structure elucidation was completed with 1D and 2D NMR spectroscopy, including 1H, 13C, gCOSY, gHSQC and gHMBC spectra. 1D NMR data of BFY3 is shown in Table 2. The 1H NMR spectrum combined with the gHSQC spectrum suggested the presence of five methyls (δH 2.04, 1.62, 1.33, 0.89, and 0.85), two methylenes with diastereotopic protons (δH 4.25, 3.98, 1.42 and 1.29), three olefinic protons (δH 6.78, 6.30 and 6.07), and three methines (δH 5.30, 3.44 and 1.72). The 13C NMR spectrum and the gHSQC spectrum indicated the presence of two carbonyl groups (δc 193.8 and 172.3), six olefinic carbons (6c 162.3, 146.0, 145.6, 122.5, 120.4 and 101.7), and six oxygenated carbons (6c 81.1, 79.2, 77.0, 73.8, 68.4, 68.3). Four exchangeable protons were revealed by the 1H NMR spectrum in DMSO-d6.
-
TABLE 2 NMR data of BFY-3 in CD3OD.a BFY-3 Positions C, type H (J in Hz) HMBC 1α 73.8, CH2 4.25, d (11.7) 3, 4a, 7, 8a 1β 3.98, d (11.7) 3, 4a, 7 3 162.3, C 4 101.7, CH 6.07, s 3, 5, 7, 8a 4a 146.0, C 5 120.4, C 6 193.8, C 7 68.2, C 8 79.2, CH 5.30, s 1, 4a, 6, 18, 19 8a 68.4, C 9 122.5, CH 6.30, d (15.7) 3,4, 4a, 11 10 145.6, CH 6.78, d (15.7) 3, 9, 11, 16 11 77.0, C 12 81.1, CH 3.44, br s 10, 11, 16, 17 13 36.4, CH 1.72, m 15 14 α 30.1, CH2 1.42, m 12, 13, 15 14 β 1.29, m 12, 13, 15 15 12.4, CH3 0.89, t (7.4) 13, 14 16 26.5, CH3 1.33, s 10, 11, 12 17 14.8, CH3 0.85, d (6.7) 12, 13, 14 18 27.1, CH3 1.62, s 6, 8 19 172.3, C 20 20.9, CH3 2.04, s 19 7-OH 8a-OH 11-OH 12-OH a1H NMR data recorded at 500 MHz, reported in ppm (multiplicity, J in Hz, integration); 13C NMR data recorded at 125 MHz; HMBC performed as gHMBCAD and recorded as positions of carbons.
Based on the degree of unsaturation, BFY-3 was determined to be a bicyclic compound with 2 carbonyl groups and six olefinic carbons. 1H-1H COSY correlations (H-13/H3-17; H-10/H-9) combined with 2D gHMBC correlations (H3-15/C-13 and C-14; H2-14/C-12, C-13 and C-15; H3-17/C-12, C-13 and C-14; and H-12/C-10, C-11 and C-17) indicated a chain with C-11, C-12, C-13, C-14 and C-15 (FIG. 4 ), while C-17 was found to connect with C-13. One of the two open valances on C-11 was assigned to the methyl group C-16, based on gHMBC correlation H-12/C-16. Further connection was built based on gHMBC correlations H-10/C-3, C-9, C-11 and C-16; H-9/C-3, C-4a, C-4, and C-11; H-4/C-3, C-5 and C-8a, which suggested a conjugated system with three olefins, containing C-10, C-9, C-3, C-4, C-4a and C-5. C-10 was found attached to C-11 based on gHMBC correlation H-10/C-16. 1H-1H COSY correlation between H-9 and H-10 supported the position of C-9 and C-10. Continuing with analysis of the gHMBC spectrum, H2-1 has correlations to C-3, C-4a and quaternary carbon C-8a. Considering the chemical shift of C-1 (δc 73.6) indicating an oxygenated carbon, a six-member ring was built with C-1, C-3, C-4, C-4a, C-8a and an oxygen. gHMBC correlation of H-8/C-1, C-4a and C-6 indicated the methine group C-8 is attached to the six-member ring. Further connection was built based on gHMBC correlations H-8/C-18, C-6; H3-18/C-6, C-8. Based on the previously built six-member-ring, a bicyclic skeleton was revealed, with C-8, C-6, C-7 (attached to Me-18) and C-5 as one of the bridges. An acetate group was found attached to C-8 based on gHMBC correlation between H-8/C-20. Me-20 was assigned based on its correlation with C-19. The chemical shifts of C-11 (δc 77.0), C-12 (δc 81.1), C-7 (δc 68.2) and C-8a (δc 68.4), combined with the information of four exchangeable protons, suggested a diol system on position C-11 and C-12, and one hydroxy group each on C-7 and C-8a. The chlorine atom was assigned to the open valence of C-5. Compared to the most related known azaphilone compounds eupenicilazaphilone C and hypocrellone A (FIG. 6 ) BFY-3 has a unique alcohol group on position C-8a. - The other new compound BFY4 was isolated as fraction M-6-3 (
FIG. 5 ). The structure was established and confirmed by X-ray crystallography. 1D 1H NMR data is shown in Table 3. -
TABLE 3 1D NMR data of M-6-3 in MeOD.a M-6-3 Position H (J in Hz) 1-CHO 9.91, s 2 3-CH3 2.03, s 4-OCH3 3.91, s 5 6.50, s 6 l′ 4.15, s 2′ 3′ 4.36, s 3′-OH 4.58, br s a1H NMR data recorded at 500 MHz, reported in ppm (multiplicity, J in Hz, integration) - Several known compounds with the same bicyclic azaphilone skeleton were isolated from the same extract. J-3, K-5-1, and I-7-4 were analyzed based on comparing 1D NMR data with the literature, along with analyzing HESIMS data. These three compounds were identified as possible isomers, based on the same molecular mass. Their NMR data matched with two known compounds eupenicilazaphilone C and hypocrellone A,18 based on coupling constants related of the chiral centers. The major difference between J-3 and K-5-1 focused on the coupling constant between H-8 and H-8a. The coupling constant value 9.9 Hz in J-3 indicated the position between H-8 and H-8a is anti, while in K-5-1 the coupling constant value is 2.9 Hz, suggesting the gauche position. The difference between J-3 and I-7-4 is the coupling constant between H-12 and H-13. The small value of coupling constant in J-3 resulted in the broad singlet of H-12 peak in 1D 1H NMR, while in I-7-4 H-12 peak showed as a doublet peak. Comparison of NMR data with the known compounds are shown in Table 4. below. J-3, K-5-1 and I-7-4 are expected to be three different diastereomers (Table 5).
-
TABLE 4 1D NMR data comparison of eupenicilazaphilone C, hypocrellone A and J-3 in DMSO- d6.a Eupenicilazaphilone C Hypocrellone A J-3 DMSO DMSO DMSO position C, type H (J in Hz) C, type H (J in Hz) H (J in Hz) 1 67.3, 3.79, dd (13.6, 67.2, 3.79, dd (13.7, 3.78, dd (13.5, CH2 10.8) CH2 10.9) 10.9) 4.49, dd (10.8, 5.0) 4.48, dd (10.8, 5.0) 4.48, dd (10.7, 4.9) 2 3 161.7, C 162.0, C 4 100.5, 6.07, s 100.1, 6.02, s 6.02, s CH CH 4a 145.0, C 145.2, C 5 118.3, C 118.1, C 6 187.4, C 187.4, C 7 74.0, C 74.0, C 8 72.9, CH 4.91, d (9.9) 72.8, CH 4.91, d (9.9) 4.91, d (9.9) 8a 35.4, CH 3.27, m 35.5, CH 3.27, m 3.27, m 9 120.7, 6.29, d (15.7) 120.2, 6.25, d (15.7) 6.25, d (15.7) CH CH 10 144.8, 6.60, d (15.7) 144.9, 6.70, d (15.7) 6.70, d (15.7) CH CH 11 75.3, C 75.0, C 12 77.5, CH 3.25, m 79.3, CH 3.24, m 3.24, m 13 35.7, CH 1.50, m 34.4, CH 1.64, m 1.64, m 14 28.6, 1.16, m 28.6, 1.17, m 1.17, m CH2 CH2 1.33, m 1.31, m 1.31, m 15 11.8, 0.81, m 11.9, 0.82, t (7.4) 0.82, t (7.4) CH3 CH3 16 25.0, 1.20, s 27.2, 1.23, s 1.23, s CH3 CH3 17 14.2, 0.81, m 14.0, 0.70, d (6.8) 0.70, d (6.7) CH3 CH3 18 19.6, 1.19, s 19.5, 1.18, s 1.18, s CH3 CH3 19 170.2, C 170.2, C 20 20.5, 2.15, s 20.5, 2.15, s 2.15, s CH3 CH3 7-OH 5.96, s 5.95, s 5.94, s 8-OH 11-OH 4.60, s 4.74, s 4.74, s 12-OH 4.44, d (6.6) 4.67, d (6.1) 4.67, d (6.1) a1H NMR data recorded at 500 MHz, reported in ppm (multiplicity, J in Hz, integration); 13C NMR data recorded at 125 MHz. -
TABLE 5 1H NMR data of I-7-4 and K-5-1 in CD3OD.a 1-7-4 K-5-1 MeOD MeOD position H (J in Hz) H (J in Hz) 1 3.82, dd (10.9, 3.79, dd (10.7, 2.3) 2.8) 4.46, dd (5.0, 5.8) 4.53, dd (4.8, 5.9) 3 4 6.13, s 6.10, s 4a 5 6 7 8 4.98, d (10.0) 5.47, d (2.9) 8a 3.38, m 3.43, m 9 6.28, d (15.7) 6.27, d (15.7) 10 6.76, d (15.7) 6.76, d (15.7) 11 12 3.41, d (2.1) 3.42, d (2.2) 13 1.71, m 1.71, m 14 1.41, m 1.41 ,m 1.28, m 1.28, m 15 0.91, t (7.4) 0.90, t (7.4) 16 1.31, s 1.42, s 17 0.85, d (6.8) 0.85, d (6.8) 18 1.25, s 1.31, s 19 20 2.19, s 2.02, s 7-OH 8-OH 11-OH 12-OH a1H NMR data recorded at 500 MHz, reported in ppm (multiplicity, J in Hz, integration). -
TABLE 6 1D NMR data of M-8-9-6 and L-8-4-8 in and MeOD and DMSO-d6, compared with known compounds geumsanol C and geusanol D.a M-8-9-6 M-8-9-6 MeOD DMSO position C, type H (J in Hz) C, type H (J, in Hz) 1 70.1, CH2 3.76, dd (10.9, 2.7) 68.7, CH2 4.58, dd (10.7, 5.4) 4.76, dd (5.4, 5.2) 3.68, dd (13.5, 11.0) 3 162.3, C 159.7, C 4 105.0, CH 5.74, s 103.7, CH 5.70, s 4a 154.7, C 151.5, C 5 116.9, CH 5.69, d (1.2) 116.2, CH 5.56, d (1.3) 6 199.4, C 197.0, C 7 75.9, C 74.5, C 8 75.7, CH 3.40, ovl 74.0, CH 3.20, ovl 8a 37.4, CH 3.05, m 36.0, CH 2.84, m 9 122.7, CH 6.18, d (15.7) 120.5, CH 6.05, d (15.7) 10 143.7, CH 6.66, d (15.7) 142.9, CH 6.53, d (15.7) 11 76.69, C 75.0, C 12 81.00, CH 3.42, ovl 79.4, CH 3.20, ovl 13 36.4, CH 1.69, m 34.6, CH 1.59, m 14 30.1, CH2 1.42, m 28.7, CH2 1.26, m 1.28, m 1.13, m 15 12.2, CH3 0.90, t (7.4) 12.0, CH3 0.76, t (7.4) 16 26.4, CH3 1.31, s 27.4, CH3 1.16, s 17 14.3, CH3 0.86, d (6.8) 14.2, CH3 0.66, d (6.8) 18 19.6, CH3 1.37, s 19.5, CH3 1.16, s 19 20 7-OH 5.17, s 8-OH 5.14, d (7.9) 11-OH 4.68, s 12-OH 4.62, d (6.1) L-8-4-8 L-8-4-8 MeOD DMSO position C, type H (J in Hz) C, type H (J, in Hz) 1 69.3, CH2 3.75, dd (10.8, 2.8) 67.7, CH2 4.39, dd (10.7, 5.1) 4.43, dd (5.2, 5.5) 3.65, dd (13.5, 11.1) 3 162.3, C 160.1, C 4 105.0, CH 5.79, s 103.8, CH 5.80, s 4a 153.9, C 151.0, C 5 117.1, CH 5.76, d (1.6) 116.3, CH 5.69, br s 6 197.2, C 195.2, C 7 75.3, C 73.6, C 8 76.2, CH 4.93, d (10.7) 74.7, CH 4.76, d (10.0) 8a 36.5, CH 1.70, m 34.8, CH 3.10, m 9 122.6, CH 6.19, d (15.7) 120.6, CH 6.08, d (15.7) 10 144.2, CH 6.66, d (15.7) 143.6, CH 6.55, d (15.7) 11 76.9, C 75.3, C 12 81.1, CH 3.41, d (1.7) 79.7, CH 3.24, br d (4.4) 13 36.5, CH 34.8, CH 1.60, m 14 30.2, CH2 1.41, m 28.9, CH2 1.28, m 1.28, m 1.16, m 15 12.4, CH3 0.90, t (7.4) 12.2, CH3 0.79, t (7.4) 16 26.5, CH3 1.31, s 27.5, CH3 1.19, s 17 14.5, CH3 0.85, d (6.8) 14.4, CH3 0.68, d (6.7) 18 19.7, CH3 1.25, s 19.4, CH3 1.09, s 19 172.6, C 171.0, C 20 20.8, CH3 2.20, s 20.7, CH3 2.12, s 7-OH 5.75, s 8-OH 11-OH 4.80, s 12-OH 4.72, d (5.8) Geumsanol C Geumsanol D DMSO DMSO position C, type H (J, in Hz) C, type H (J, in Hz) 1 68.5, CH2 4.62, ovl 67.3, CH2 4.42, dd (10.7, 5.2) 3.73, dd (13.5, 10.8) 3.67, dd (13.5, 10.8) 3 159.5, C 159.8, C 4 103.5, CH 5.74, s 104.4, CH 5.81, s 4a 151.1, C 150.2, C 5 116.0, CH 5.59, d (1.2) 115.9, CH 5.68, d (1.7) 6 196.7, C 194.5, C 7 74.3, C 73.2, C 8 73.9, CH 3.24, ovl 74.3, CH 4.77, d (9.9) 8a 35.9, CH 2.89, m 34.4, CH 3.12, m 9 120.3, CH 6.09, d (15.7) 120.1, CH 6.11, d (15.7) 10 142.7, CH 6.57, d (15.7) 143.2, CH 6.57, d (15.7) 11 74.8, C 74.8, C 12 79.2, CH 3.24, ovl 79.2, CH 3.24, dd (5.9, 1.5) 13 34.4, CH 1.63, m 34.4, CH 1.61, m 14 28.5, CH2 1.31, m 28.6, CH2 1.31, m 1.18, m 1.18, m 15 11.8, CH3 0.82, t (7.4) 11.9, CH3 0.81, t (7.4) 16 27.3, CH3 1.21, s 27.2, CH3 1.21, s 17 14.9, CH3 0.71, d (6.8) 14.0, CH3 0.70, d (6.8) 18 19.3, CH3 1.20. s 19.0, CH3 1.10, s 19 170.3, C 20 20.5, CH3 2.14, s 7-OH 5.18, s 5.62, s 8-OH 5.10, d (8.3) 11-OH 4.66, s 4.68, s 12-OH 4.62, ovl 4.62, d (6.0) a1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J in Hz, integration); 13C recorded at 125 MHz.
M-8-9-6 was identified to have same structure of the known compound geumsanol C or its isomer because the 1D proton and carbon NMR data matched with guemsanol C, along with the matching molecular mass. 19 Compared to the 1H NMR spectrum of M-8-9-6, L-8-4-8 has an acetyl methyl group with a δH 2.20 in CD3OD. Further comparison of the NMR spectrum indicated L-8-4-8 matched with that of geumsanol D (2.26), including chemical shifts and coupling constants. L-8-4-8 was identified as geumsanol D or its isomer.19 The 1D NMR data is shown in Table 5. - Fraction M-8-13-5 was isolated as a dark red solid. After comparing 1D NMR data with the literature, M-8-13-5 matched with a known compound isochromophilone IX, which indicated the compound M-8-13-5 is same or an isomer of isochromophilone IX. Isochromophione IX was first isolated in 2003 and showed inhibition against MRSA with MIC of 50 μg/mL.20 Comparison of 1D NMR data between M-8-13-5 and isochromophilone IX is shown in Table 7.
-
TABLE 7 1D NMR data of M-8-13-5 and isochromophilone IX in CDCl3.a M-8-13-5 Isochromophilone IX CDCl3 CDCl3 Position C, type H (J in Hz) C, type H (J in Hz) 1 141.4, CH 7.83, s 141.2, CH 7.80, s 3 144.9, C 148.1, C 4 111.5, CH 7.05, s 111.5, CH 7.05, s 4a 148.1, C 144.7, C 5 102.0, C 102.1, C 6 184.3, C 184.4, C 7 84.8, C 84.7, C 8 193.8, C 193.8, C 8a 114.8, C 114.9, C 9 114.4, CH 6.30, d (15.3) 114.3, CH 6.28, d (15.0) 10 145.4, CH 6.99, d (15.3) 145.5, CH 6.99, d (15.0) 11 132.0, C 132.0, C 12 148.3, CH 5.72, d (9.7) 148.4, CH 5.71, br d (9.5) 13 35.0, CH 2.49, m 35.0, CH 2.47, m 14 30.0, CH2 1.45, m 30.0, CH2 1.44, ddq (13.0, 6.0, 8.0) 1.37, m 1.34, ddq (13.0, 6.0, 8.0) 15 12.0, CH3 0.89, t (7.4) 12.0, CH3 0.88, t (8.0) 16 20.2, CH3 1.03, d (6.7) 20.2, CH3 1.02, d (6.5) 17 12.5, CH3 1.88, s 12.5, CH3 1.87, s 18 23.2, CH3 1.55, s 23.2, CH3 1.55, s 7-OAc 170.3, C 170.2, C 7-OAc 20.3, CH3 2.16, s 20.3, CH3 2.16, s l′ 53.4, CH2 3.99, t (7.4) 53.4, CH2 3.96, t (7.5) 2′ 25.1, CH2 2.07, m 25.0, CH2 2.05, m 3′ 30.2, CH2 2.49, t (6.2) 30.0, CH2 2.51, t (6.5) 4′ 175.4, C 175.2, C a1H NMR data recorded at 500 MHz, reported in ppm (multiplicity, J in Hz, integration); 13C NMR data recorded at 125 MHz.
Several known compounds with identified stereochemistry were also isolated from the same fungal extract. Fraction D, confirmed as 2,4-dihyroxy-6-(5,7-dimethyl-2-oxo-trans-3-trans-5-nonadienyl)-3-methylbenzaldehyde,21 was the first isolated compound from this fungal extract. It was reported to induce severely impaired heart morphology and curved trunk in exposed zebrafish embryos, with no reported TB bioactivity data. The structure was confirmed by X-ray crystallography. -
TABLE 8 1D NMR data of D and 2,4-dihyroxy-6-(5,7-dimethy1-2-oxo-trans-3- trans-5- nonadieny1)-3-methylbenzaldehyde in CDCl3.a CDCl3 CDCl3 position H (J in Hz) H (J in Hz) 2-OH 12.63, s 12.64, s 1-CHO 9.86, s 9.85, s 4′-H 7.35, d (15.7) 7.34, d (15.7) 4-OH 6.55, s 3′-H 6.19, d (15.7) 6.18, d (15.7) 5-H 6.18,s 6.16, s 6′-H 5.82, d (9.7) 5.57, d (9.9) l′-H 4.08, s 4.07, s 7′-H 2.47, m 2.48, m 3-CH3 2.05, s 2.05, s 5′-CH3 1.80, s 1.79, s 8′-H 1.43, m 1.40, m 7′-CH3 1.00, d (6.4) 1.00, d (6.6) 9′-H 0.86, t (7.1) 0.85, t (7.2) a1H NMR data recorded at 400 MHz, reported in ppm (multiplicity, J in Hz, integration)
Fraction O-7 was isolated as a dark red crystal. HRESIMS suggested m/z 434.1796 [M+H]+, calculated 434.1734, indicating the molecular formula is C23H28NO5Cl. The 1H NMR spectrum of 0-7 was compared to the literature and it matched with a known compound isochromophilone VI based on chemical shifts, peak splitting pattern and coupling constants. X-ray crystallography determined that 0-7 is Isochromophilone VI, which was first reported in 1995.22 It was reported to have bioactivity against S. pyogenes and S. typhimurium, while TB activity was not tested. 1D NMR data is shown in Table 2.7. along with data of isochromophilone VI.20 -
TABLE 2.8 1D NMR data of O-7 and isochromophilone VI in CDCl3.a O-7 Isochromophilone VI CDCl3 CDCl3 Position H (J in Hz) C, type H (J in Hz) 1 7.86, s 142.3, CH 7.91, s 3 145.5, C 4 7.04, s 111.9, CH 7.05, s 4a 149.0, C 5 101.6, C 6 184.2, C 7 84.8, C 8 193.9, C 8a 114.7, C 9 6.26, d (15.4) 114.9, CH 6.27, d (15.3) 10 6.95, d (15.2) 145.5, CH 6.94, d (15.3) 11 131.7, C 12 5.71, d (9.6) 148.3, CH 5.71, br d (9.6) 13 2.49, m 35.0, CH 2.47, m 14 1.44, m 30.0, CH2 1.44, ddq (13.5, 7.2, 7.5) 1.34, m 1.34, ddq (13.5, 5.4, 7.5) 15 0.89, t (7.3) 12.0, CH3 0.88, t (7.5) 16 1.03, d (6.5) 20.2, CH3 1.02, d (6.0) 17 1.86, s 12.6, CH3 1.84, s 18 1.57, s 23.3, CH3 1.54, s 7-Oac 170.4, C 7-OAc 2.17, s 20.3, CH3 2.15, s l′ 4.04, m 55.7, CH2 4.05, ddd (14.4, 4.8, 4.8) 4.02, ddd (12.9, 4.8, 4.8) 2′ 3.97, m 60.7, CH2 3.92, ddd (12.9, 4.8, 4.8) 3.91, ddd (12.9, 4.8, 4.8) a1H NMR data recorded at 500 MHz, reported in ppm (multiplicity, J in Hz, integration). - Fraction F-8-3 was eluted from reverse phase with methanol and water, and it was crystallized. Further data collected by X-ray crystallography indicated F-8-3 is a known compound 4-hydroxy-6-methoxy-5-methyl-1(3H)-isobenzofuranone.23 1H NMR data was not able to obtain resulting from limited mass.
- The major compound from this fungal extract was isolated from fraction G. The fraction G-4 (was recrystallized as snow-flake shape. The structure was identified by X-ray crystallography as pencolide, a well-studied fungal metabolite since 1963.24 It was reported to show inhibition to S. pyogenes, S. aureus, S. typhimurium E. coli and C. albicans. 24 1 D NMR data is shown in Table 9. Comparing to the literature data of pencolide, G-4 matched with pencolide with chemical shift and coupling constants.
-
TABLE 9 1D NMR data of G-4 in CDCl3,a compared with known compound pencolide.26 G-4 Pencolide CDCl3 CDCl3 Position H (J in Hz) C, type H (J in Hz) 1 167.3, C 2 123, C 3 7.42, q (7.1) 145.3, CH 7.40, q (7.0) 4 1.82, d (7.1) 14.7, CH3 1.81, d (7.0) 2′ 170.2, C 3′ 146.7, C 4′ 6.46, q (1.8) 128.3, CH 6.46, q (2.0) 5′ 169.1, C 6′ 2.14, d (1.7) 11.7, CH3 2.13, d (2.0) a1H NMR data recorded at 400 MHz, reported in ppm (multiplicity, J in Hz, integration). - Compound J-3, O-7, D, F-8-3, M-6-3 and G-4 were tested against replicating Mtb. Cytotoxicity assay was screened with J774 macrophages. F-8-3, M-6-3 and G-4 were also screened against Mab. Results are shown below in Table 10.
-
TABLE 10 TB bioactivity data of pure compounds isolated from EG12-25A-3-DNMT extract. MIC (Mtb-rep) IC50 (J774) M. abscessus Compound (μg/ml) (μg/ml) (μg/ml) EtOAc-J-3 ~150 ~300 EtOAc-O-7 18.6 ~200 EtOAc-D ~50 ~200 EtOAc-F-8-3 200 200 EtOAc-G-4 50 100 EtOAc-M-6-3 50 100 - Among these tested samples, 0-7, determined as the known compound isochromophilone IV, showed MIC=18 μg/ml, IC50=200 μg/mL for a selectivity index (SI)=10.78 (
FIG. 11 ). This result could be considered as a starting point for potential hit-to-lead optimization. At the same time, isochromophilone VI is the first naturally occurring nitrogen-containing azaphilone derivative that is reported with antimycobacterial activity. - Under epigenetic treatment, 11 compounds were isolated from the EG12-25A-3-DNMT extract. Among these compounds, two compounds, BFY-3 and BFY-4 have new skeletons. The relative stereochemistry on position C-12 and C-13 would be determined by Murata's method. C—H coupling constants will be obtained by HSQMBC spectra. The acetate group attached on C-8 would be hydrolysed to a secondary alcohol. Acetonide formation would be applied on C-7/C-8 and C-11/C-12 to determine the relative stereochemistry. Mosher's method will be applied to the secondary alcohols on C-8 and C-12 to indicate the absolute stereochemistry, and further indicate the absolute stereochemistry of C-7, C-11 and C-13. Five compounds, J-3, I-7-4, K-5-1, M-8-9-6 and L-8-4-8 were identified as known compounds, and the stereochemistry needs to be further determined using the method described above. At the same time, computational calculations would be applied to predict chemical shifts with different diastereomers. Four crystals were isolated, including D, O-7, F-8-3 and G-4. Six of the pure compounds were tested against replicating Mtb, Mab and J774. O-7 showed promising bioactivity against replicating Mtb, with low cytotoxicity, which makes it promising as a lead compound for further drug development.
- Each of the below publications is hereby incorporated by reference in its entirety for all purposes:
- (1) Elkington, P; Tebruegge, M; Mansour S, Tuberculosis: an infection-initiated autoimmune disease? Trends. Immunol., 2016, 37, 815-818
- (2) Kiazyk, S.; Ball, T. Latent tuberculosis infection: an overview. Can. Commun. Dis. Rep. 2017, 43, 62-66.
- (3) Khan, M K, Islam, M N, Ferdous, J, Alam, M M. An overview on epidemiology of tuberculosis. Mymensingh Med. J. 2019, 28, 259-266. https://europepmc.org/article/med/30755580 (accessed Jan. 6, 2020).
- (4) Churchyard, G. J.; Swindells, S. Controlling Latent TB tuberculosis infection in high-burden countries: a neglected strategy to end TB. PLoS Med. 2019, 16, e1002787. https://doi.org/10.1371/journal.pmed.1002787.
- (5) Lee, M.; Mok, J.; Kim, D. K.; Shim, T. S.; Koh, W.-J.; Jeon, D.; Lee, T.; Lee, S. H.; Kim, J. S.; Park, J. S.; Lee, J. Y.; Kim, S. Y.; Lee, J. H.; Jo, K.-W.; Jhun, B. W.; Kang, Y. A.; Ahn, J. H.; Kim, C.-K.; Shin, S.; Song, T.; Shin, S. J.; Kim, Y. R.; Ahn, H.; Hahn, S.; Won, H. J.; Jang, J. Y.; Cho, S. N.; Yim, J.-J. Delamanid, Linezolid, Levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (treatment shortening of MDR-TB using existing and new drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label
clinical trial Trials 2019, 20, 57. https://doi.org/10.1186/s13063-018-3053-1. - (6) Tsang, C. A.; Shah, N.; Armstrong, L. R.; Marks, S. M. Eligibility for a shorter treatment regimen for multidrug-resistant tuberculosis in the united states, 2011-2016. Clin. Infect. Dis. 2020, 70, 907-916 https://doi.org/10.1093/cid/ciz263.
- (7) Asif, M. An overview on fluoroquinolone drugs for the treatment of tubercular infection. J. Med. Chem. Sci. 2019, 2, 172-176. https://doi.org/10.26655/jmchemsci.2019.8.7.
- (8) Cheng, Z.; Pan, J.-H.; Tang, W.; Chen, Q.; Lin, Y. Biodiversity and biotechnological potential of mangrove-associated fungi. J. For. Res. 2009, 20, 63-72. https://doi.org/10.1007/s11676-009-0012-4.
- (9) Mangrove Species Profiles https://www.floridamuseum.ufl.edu/southflorida/habitats/mangroves/species/(accessed Jan. 7, 2020).
- (10) Kumaresan, V. Occurrence, Distribution and bioactive potential of mangrove fungal endophytes: an appraisal. KAVAKA, 2017, 48, 44-49.
- (11) Wen, S.; Fan, W.; Guo, H.; Huang, C.; Yan, Z.; Long, Y. Two new secondary metabolites from the mangrove endophytic fungus pleosporales Sp. SK7. Nat. Prod. Res. 2019, 0, 1-7. https://doi.org/10.1080/14786419.2019.1598993.
- (12) Zhang, L.; Niaz, S. I.; Khan, D.; Wang, Z.; Zhu, Y.; Zhou, H.; Lin, Y.; Li, J.; Liu, L. Induction of diverse bioactive secondary metabolites from the mangrove endophytic fungus trichoderma sp. (strain 307) by co-cultivation with acinetobacter johnsonii (strain B2). Mar. Drugs. 2017, 15, 35. https://doi.org/10.3390/md15020035.
- (13) Ding, B.; Wang, Z.; Huang, X.; Liu, Y.; Chen, W.; She, Z. Bioactive α-pyrone meroterpenoids from mangrove endophytic fungus penicillium sp. Nat. Prod. Res. 2016, 30, 2805-2812. https://doi.org/10.1080/14786419.2016.1164702.
- (14) Björn, B. H.; Barbara, B.; Regina, H.; Axel, Z. Big effects from small changes: possible ways to explore nature's chemical diversity. ChemBioChem. 2002, 3, 619-627. haps://doi.org/10.1002/1439-7633(20020703)3:7<619::AID-CBIC619>3.0.CO;2-9.
- (15) Tresner, H. D.; Hayes, J. A. Sodium chloride tolerance of terrestrial fungi. Appl. Microbiol. 1971, 22, 210-213.
- (16) Epigenetic modification increases susceptibility to obesity and predicts fatty liver https://medicalxpress.com/news/2016-05-epigenetic-modification-susceptibility-obesity-fatty.html (accessed Jan. 6, 2020).
- (17) Demers, D. H.; Knestrick, M. A.; Fleeman, R.; Tawfik, R.; Azhari, A.; Souza, A.; Vesely, B.; Netherton, M.; Gupta, R.; Colon, B. L.; Rice, C. A.; Rodriguez-Perez, M. A.; Rohde, K. H.; Kyle, D. E.; Shaw, L. N.; Baker, B. J. Exploitation of mangrove endophytic fungi for infectious disease drug discovery. Mar. Drugs. 2018, 16, 376. https://doi.org/10.3390/md16100376.
- (18) Gu, B.-B.; wu, Y.; Tang, J.; Jiao, W.; Li, L.; Sun, F.; Wang, S.-P.; Yang, F.; Lin, H.-W. Azaphilone and isocoumarin derivatives from the sponge-derived fungus eupenicillium sp. 6A-9. Tetrahedron. Lett. 2018, 59, 3345-3348. https://doi.org/10.1016/j.tetlet.2018.06.057.
- (19) Son, S.; Ko, S.-K.; Kim, J. W.; Lee, J. K.; Jang, M.; Ryoo, I.-J.; Hwang, G. J.; Kwon, M. C.; Shin, K.-S.; Futamura, Y.; Hong, Y.-S.; Oh, H.; Kim, B. Y.; Ueki, M.; Takahashi, S.; Osada, H.; Jang, J.-H.; Ahn, J. S. Structures and biological activities of azaphilones produced by penicillium sp. kcb11a109 from a ginseng field. Phytochemistry 2016, 122, 154-164. https://doi.org/10.1016/j.phytochem.2015.12.008.
- (20) Michael, A. P.; Grace, E. J.; Kotiw, M.; Barrow, R. A. Isochromophilone IX, a novel gaba-containing metabolite isolated from a cultured fungus, penicillium sp. Aust. J. Chem. 2003, 56, 13. https://doi.org/10.1071/CH02021.
- (21) Matsuzaki, K.; Tahara, H.; Inokoshi, J.; Tanaka, H.; Masuma, R.; Omura, S. New brominated and halogen-less derivatives and structure-activity relationship of azaphilones inhibiting gp120-cd4 binding. J. Antibiot. 1998, 51, 1004-1011. https://doi.org/10.7164/antibiotics.51.1004.
- (22) Arai, N.; Shiomi, K.; Tomoda, H.; Tabata, N.; Yang, D. J.; Masuma, R.; Kawakubo, T.; Omura, S. Isochromophilones III-VI, Inhibitors of acyl-coa: cholesterol acyltransferase produced by penicillium multicolor fo-3216. J. Antibiot. 1995, 48, 696-702. https://doi.org/10.7164/antibiotics 0.48.696.
- (23) Frisvad, J. C.; Smedsgaard, J.; Larsen, T. O.; Samson, R. A. Mycotoxins, drugs and other extrolites produced by species in penicillium subgenus penicillium. Stud. Mycol., 2004, 49, 201-241.
- (24) Birkinshaw, J. H.; Kalyanpur, M. G.; Stickings, C. E. Studies in the biochemistry of microorganisms. 113. pencolide, a nitrogen-containing metabolite of penicillium multicolor grigorieva-manilova and poradielova. Biochem. J. 1963, 86, 237-243.
- (25) Lucas, E. M. F.; Castro, M. C. M. de; Takahashi, J. A. Antimicrobial properties of sclerotiorin, isochromophilone VI and pencolide, metabolites from a brazilian cerrado isolate of penicillium sclerotiorum van beyma. Braz. J. Microbiol. 2007, 38, 785-789. http s://doi.org/10.1590/S 1517-83822007000400036.
- (26) Wang, X.; Sena Filho, J. G.; Hoover, A. R.; King, J. B.; Ellis, T. K.; Powell, D. R.; Cichewicz, R. H. Chemical epigenetics alters the secondary metabolite composition of guttate excreted by an atlantic-forest-soil-derived penicillium citreonigrum. J. Nat. Prod. 2010, 73, 942-948. https://doi.org/10.1021/np100142h.
- The compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims and any compositions and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compositions and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative compositions and method steps disclosed herein are specifically described, other combinations of the compositions and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein or less, however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.
- The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments of the invention and are also disclosed. Other than in the examples, or where otherwise noted, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, to be construed in light of the number of significant digits and ordinary rounding approaches.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/375,403 US20220016075A1 (en) | 2020-07-14 | 2021-07-14 | Methods for the treatment of mycobacterium infections |
US17/713,576 US20220226284A1 (en) | 2020-07-14 | 2022-04-05 | Methods for the treatment of mycobacterium infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063051476P | 2020-07-14 | 2020-07-14 | |
US17/375,403 US20220016075A1 (en) | 2020-07-14 | 2021-07-14 | Methods for the treatment of mycobacterium infections |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/713,576 Continuation US20220226284A1 (en) | 2020-07-14 | 2022-04-05 | Methods for the treatment of mycobacterium infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220016075A1 true US20220016075A1 (en) | 2022-01-20 |
Family
ID=79291724
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/375,403 Abandoned US20220016075A1 (en) | 2020-07-14 | 2021-07-14 | Methods for the treatment of mycobacterium infections |
US17/713,576 Pending US20220226284A1 (en) | 2020-07-14 | 2022-04-05 | Methods for the treatment of mycobacterium infections |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/713,576 Pending US20220226284A1 (en) | 2020-07-14 | 2022-04-05 | Methods for the treatment of mycobacterium infections |
Country Status (1)
Country | Link |
---|---|
US (2) | US20220016075A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960729A (en) * | 2022-12-09 | 2023-04-14 | 济南大学 | Azotone compound with effect of promoting peripheral nerve injury repair and preparation method thereof |
WO2023160112A1 (en) * | 2022-02-28 | 2023-08-31 | 中国海洋大学 | Azaphilone compound and use thereof in preparation of anti-tumor drugs |
EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
-
2021
- 2021-07-14 US US17/375,403 patent/US20220016075A1/en not_active Abandoned
-
2022
- 2022-04-05 US US17/713,576 patent/US20220226284A1/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023160112A1 (en) * | 2022-02-28 | 2023-08-31 | 中国海洋大学 | Azaphilone compound and use thereof in preparation of anti-tumor drugs |
EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
CN115960729A (en) * | 2022-12-09 | 2023-04-14 | 济南大学 | Azotone compound with effect of promoting peripheral nerve injury repair and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US20220226284A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220016075A1 (en) | Methods for the treatment of mycobacterium infections | |
EP2512461B1 (en) | Chalcones as enhancer of antimicrobial agents | |
WO2006085838A1 (en) | 18-membered macrocycles and analogs thereof | |
US20230233536A1 (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria | |
JP2014132023A (en) | Pharmaceutical compositions | |
CA2728328A1 (en) | Treatment of antibiotic-resistant bacteria infection | |
US9169182B2 (en) | Chrysophaentin analogs that inhibit FtsZ protein | |
US20210317099A1 (en) | Safer, potent, and fast acting antimicrobial agents | |
EP2539305B1 (en) | Chrysophaentin antimicrobial compounds that inhibit ftsz protein | |
US20220081470A1 (en) | Thiazolyl peptides for the treatment nontuberculous mycobacterial infections | |
US9920025B2 (en) | Antibiotic | |
WO2017182828A1 (en) | Antimicrobial agents | |
WO2004080455A1 (en) | Antibacterial agent and anticancer agent | |
WO2011063615A1 (en) | Macrocyclic amides, pharmaceutical compositions, preparation methods and uses thereof | |
US20200330444A1 (en) | Deuterated compounds for treating pain and related diseases and conditions, and compositions and methods thereof | |
KR102488654B1 (en) | Pharmaceutical composition containing micrococcin compound and method for preparing micrococcin compound | |
US5962515A (en) | Process for isolation and synthesis of 1-(3,4 methylenedioxy-phenyl)-1E-tetradecene and its analogues and their activities against tumors and infections | |
KR101356945B1 (en) | Polyhydroxylated macrolides from Seimatosporium discosioides and its use | |
CN117105930B (en) | 3, 13-disubstituted berberine derivative, and preparation method and application thereof | |
US20230094006A1 (en) | Pharmaceutical composition containing macrolide compound, production method therefor, and method using same | |
EP4342484A1 (en) | Pharmaceutical composition comprising macrocosine compound and method for preparing macrocosine compound | |
US20210340116A1 (en) | Compounds for the treatment of clostridium difficile infection | |
US20230398139A1 (en) | Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections | |
US10537545B2 (en) | Ceramide derivatives as anticancer agents | |
WO2023055940A1 (en) | Modulators of molecular targets expressed in metabolic and inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: UNIVERSITY OF SOUTH FLORIDA, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAKER, BILL J.;YANG, BINGJIE;SIGNING DATES FROM 20220502 TO 20230206;REEL/FRAME:066265/0724 |
|
AS | Assignment |
Owner name: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROHDE, KYLE;FUSE, MARISA;REEL/FRAME:066569/0378 Effective date: 20220519 |